



# Tomorrow, better treatment for patients with lymphoma and CLL-WM

---

2024 ACTIVITY REPORT  
LYSA-LYSARC

TOGETHER AGAINST LYMPHOMA



# 01

**Editorial**.....p 4

# 02

**Challenges in Lymphomas and CLL-WM research**

- 01 Key Figures on Lymphoma and CLL-WM .....p 6
- 02 Public Health and R&D: Major Challenges .....p 7
- 03 Economic Dimensions .....p 7

# 03

**LYSA-LYSARC Expertise in Lymphomas and CLL-WM**

- 01 The LYSA-LYSARC Intergroup .....p 8
- 02 LYSA .....p 10
- 03 LYSARC .....p 14

# 04

**Looking back on 2024**

- 01 Launch of Two Major Projects in Follicular Lymphoma .....p 16
- 02 Multiple Other Scientific Advances Worth Noting .....p 18
- 03 Structural Actions for Strengthened Impact .....p 20
- 04 Successful Synergies Between Researchers in France and Internationally .....p 21
- 05 8<sup>th</sup> LYSA Days – A Success .....p 22
- 06 Tribute to Donors and Other Solidarity Initiatives .....p 23
- 07 Exceptional Visibility at Conferences .....p 24
- 08 Dense and Recognized Scientific Production .....p 26
- 09 Visibility in Specialized and General Media .....p 28

# 06

**LYSA centers and LYSA-LYSARC platforms activities**

- 01 LYSA investigating centers activities .....p 34
- 02 Bioinformatics platform activities .....p 35
- 03 LYSA-P/LYSA-BIO platform activities .....p 36
- 04 LYSA-IM platform activities .....p 37

# 05

**Rapport scientifique 2024**

- 01 Overview of 2024 scientific projects .....p 31
- 02 Focus on 3 non-interventional studies in recruitment .....p 31
- 03 Focus on 7 interventional studies in recruitment .....p 32
- 04 Focus on 114 statistical analyses .....p 32
- 05 Focus on project ideas .....p 33
- 06 Focus on research valorizations .....p 33

**Appendix** .....p 38



This table of contents is interactive



By clicking on the icons in this document, you will find links, additional information and a video.





# 01 Editorial

## Message from the president of LYSA and LYSARC, Pr. Franck Morschhauser



”

We are pleased to present this new activity report from LYSA-LYSARC. The year 2024 was rich and stimulating, marked by scientific achievements and challenges successfully met through collective effort.

It would be impossible to summarize the full scope of our activities in just a few lines. Instead, we invite you to look back at three key highlights from the year, each reflecting an essential aspect of our intergroup:

→ **New openings in Chronic Lymphocytic Leukemia (CLL) and Waldenström's Macroglobulinemia (WM)**  
This year saw the creation of a new LYSA commission dedicated to CLL and WM, initiated by a collective decision of the FILO CLL/WM committee. The aim was to unify projects related to lymphoid malignancies and to conduct this new research within the LYSA / LYSARC.

→ **The Scientific Excellence Showcased at the 8th LYSA Days**

2024 began with the success of the 8th LYSA Days, which brilliantly showcased the diversity and quality of the work carried out by our intergroup.

More than twenty projects were presented: clinical studies in the finalization phase such as **BICAR** in diffuse large B-cell lymphoma, promising new trials like **GLOASIS** in mantle cell lymphoma, as well as several studies using data from our **DESCAR-T** and **REALYSA** registries.

We must commend the collective effort of our members and collaborators, without whom this event could not have been such a success. Next meet-up: Toulouse in October 2025!

→ **A Concrete Commitment to Innovation: the Cutting-Edge BIDIFLY Program**

The first quarter of 2024 concluded with the launch conference of BIDIFLY, an innovative research program born from a partnership between our intergroup and the American foundation IFLI (Institute for Follicular Lymphoma Innovation).

This project aims to advance research on follicular lymphoma through innovation.

The teams from our LYSA-LYSARC research platforms are leveraging new technologies to generate an unprecedented volume of multi-omics data, which will then enter an artificial intelligence-driven analysis phase.

We are excited about the scale-up of this ambitious four-year program, involving top-tier partners: **IFLI, Institut Carnot CALYM, INSERM, Institut Curie, Institut Paoli-Calmettes, Rennes University Hospital, and Toulouse University Hospital.**

→ **The Collaborative Momentum at the Heart of the MorningLyte Pivotal Study**

In November 2024, we had the pleasure of hosting the first post-launch meeting of the **MorningLyte** Phase III study at our headquarters. This project perfectly embodies the spirit of collaboration that drives our intergroup: it is the result of a strong international partnership built with committed and complementary players.

The study was co-designed by our intergroup and our colleagues from the German cooperative group **GLA**, in partnership with **Roche Laboratories**. We also benefit from the valuable support of the cooperative groups **SAKK (Switzerland), AGMT (Germany), and GELTAMO (Spain)**, as well as the pharmaceutical company **CHUGAI PHARMACEUTICAL in Japan**.

Collective engagement is strong, with the first patient enrollments initiated in 2024 and a planned follow-up period of at least seven years. Continuing the legacy of our **PRIMA** and **RELEVANCE** trials, the MorningLyte project carries major promise: the potential redefinition of first-line treatment standards for follicular lymphoma. The combination under study: a **CD20xCD3 bispecific antibody** paired with an **immunomodulator**.

To conclude, these three highlights fully illustrate the commitment of our teams, our scientific rigor, and our determination to innovate in the service of patients. We approach 2025 with confidence, enthusiasm and determination, to continue advancing lymphoma research.

## Message from the General Director of LYSARC, Florence Agostino-Etchetto



”

“I am pleased and honored by the trust placed in me by Professor Franck Morschhauser, President of LYSA, in choosing me for this position. I would like to thank him, as well as the members of the board, for giving me the opportunity to join an organization whose excellence and strategic positioning have enabled major advances in the treatment of lymphomas.

I am delighted to have begun working with all the LYSARC collaborators, who are currently implementing numerous clinical trials. The initial exchanges with LYSA and our European partners have already allowed us to outline ambitious projects that will help strengthen LYSARC's position as a key international player in lymphoma and CLL-WM research.”

### APPOINTMENT TO THE MANAGEMENT OF LYSARC

**Florence Agostino-Etchetto took up her position as General Director of LYSARC in October 2024. The entire team is pleased to continue the work of the intergroup at her side, with the same energy and commitment in the fight against lymphomas.**

Florence previously served as General Director of Lyonbiopôle for more than 11 years. She led numerous initiatives to fund public/private R&D projects and promoted financing for healthcare companies, particularly SMEs, with the goal of energizing the health innovation ecosystem in the Auvergne-Rhône-Alpes region.

She also contributed to the development of several key proposals as part of France 2030, including the French biocluster project for Emerging Infectious Diseases.


Earlier in her career, she held several leadership roles at the Hospices Civils de Lyon, notably in the Department of Biology and Anatomical Pathology, and in the Department of Clinical Research and Innovation, further strengthening her expertise in medical management and innovation.




# 02 Challenges in Lymphomas and CLL-WM research

## 01 Key Figures on Lymphoma and CLL-WM

Epidemiological data on lymphomas highlight the major importance of the fight against these cancers on a global scale. The French scientific community, in close collaboration with international researchers, is fully committed to advancing knowledge and improving patient care.



## 02 Public Health and R&D: Major Challenges



Although significant progress has been made in understanding and managing lymphomas, these cancers remain a major public health concern and a particularly complex bioclinical field. Ongoing efforts are essential to meet the numerous challenges in fundamental, translational, and clinical research.

**PATHOPHYSIOLOGICAL CHALLENGES:** Deepening the understanding of the mechanisms involved in the development of lymphomas and identifying risk factors.

**DIAGNOSTIC CHALLENGES:** Addressing the diversity of lymphomas (more than 80 types), improve diagnostic timelines and accuracy, particularly through the use of artificial intelligence.

**PROGNOSTIC CHALLENGES:** Optimizing treatment personalization by identifying the right treatment for the right patient at the right time (biomarker research) and reducing therapy-related toxicity.

**THERAPEUTIC CHALLENGES:** Exploring new therapeutic targets, developing innovative treatments (immunotherapy, CAR-T cells, etc.), and designing new therapeutic combinations.

4. Market research report by Nova One Advisor - 2023.

## 03 Economic Dimensions



Cancer research represents a major economic issue for pharmaceutical and biotechnology stakeholders worldwide.

Innovation in this field requires high-level expertise—an area where academic research can make a significant contribution.



### IMMUNO-ONCOLOGY MARKET

A key growth driver for the global pharmaceutical and biotechnology industry

Global market valued at approximately **\$222 billion in 2023<sup>4</sup>**

A dynamic market projected to reach around **\$521 billion by 2033<sup>4</sup>**

Growing role of emerging biopharma companies (startups/SMEs/mid-sized firms)

Strong emergence of the Asian market, highly competitive and aggressive



### GROWTH STRATEGIES

Expansion to multiple indications

Strategic repositioning of drug candidates/approved medications

Accelerated registration (niche strategies, from/to lymphoma)

Cost reduction (large-scale Phase III trials targeting registration)

Lowering the high failure rate of clinical trials (currently 80–90%)



### MARKET DEMAND

Integrated care/research expertise networks enabling:

- Biological streamlining of clinical trial design
- Reconnection between discovery, innovation, and translation segments
- Bridging academic and industrial standards and expertise



# 03 LYSA-LYSARC

## Expertise in Lymphomas and CLL-WM



### 01 The LYSA-LYSARC Intergroup

#### A DRIVING FORCE IN LYMPHOMA AND CLL-WM RESEARCH

LYSA and LYSAARC form a leading multidisciplinary ecosystem dedicated to innovation in lymphoma research. LYSAARC plays a central role in the implementation of clinical trials, data analysis, and the development of new therapeutic strategies. It also acts as a sponsor and initiator of research projects, actively contributing to the exploration of new diagnostic and therapeutic approaches.

Together, LYSA and LYSAARC are certified by the French National Cancer Institute (INCa) as a "French cooperative intergroup of international scope in the field of clinical cancer research," a testament to their expertise and global impact.

#### A BROAD FIELD OF ACTION IN SERVICE OF INNOVATION

LYSAARC leads the implementation and management of clinical studies, whether interventional or non-interventional, to advance biological and medical knowledge on lymphomas.

It is involved in all phases of clinical trials—from the first administration of new treatments in humans to the establishment of standard therapeutic strategies.

Beyond clinical research, LYSAARC operates specialized platforms in **pathology, biology, and imaging**, allowing it to fully leverage technological advances to refine diagnoses, better understand the disease, and optimize treatments.

LYSAARC also coordinates real-world data registries in partnership with other lymphoma research stakeholders, thus fostering a deeper understanding of disease progression and its impact on patients. At the same time, it manages a large annual portfolio of **Data Reuse Studies (DRS)**, maximizing the use of knowledge derived from past clinical trials to accelerate therapeutic progress.

Thanks to LYSAARC's expertise and LYSA's strategic vision, the intergroup stands out as a key player in the fight against lymphomas—constantly pushing the boundaries of medical innovation.

#### OVERVIEW OF AVAILABLE RESOURCES

The LYSA-LYSARC intergroup is part of the **Institut Carnot CALYM**, alongside 18 public laboratories conducting cutting-edge research in the field of lymphomas and CLL-WM. This academic network of excellence enables the pooling of strategic resources and offers a unique research and development (R&D) capacity, thereby fostering innovation and advancing knowledge in this field.

#### > COLLECTIONS & DATABASES



Focus on flagship collections

- **TENOMIC/LYSATOMIC (T-cell lymphomas)** : > 1,000 patients
- **Bioclinical databases**: > 23,000 tumor samples: FFPE, frozen, TMA, blood, plasma, DNA/RNA; clinically annotated and characterized (phenotypes, genotypes, ...)
- **Imaging database**: > 42,000 medical imaging exams available (PET/CT, CT, MRI)

#### > PLATEFORMES



- **LYSA-IM**: imaging
- **LYSA-P**: pathology
- **LYSA-BIO**: biology
- **Bioinformatics**: pipelines, machine learning, artificial intelligence

#### Resources outside LYSAARC

- **Think Tank Innovation**: project idea maturation – CALYM
- **French Connect**: harmonized ctDNA analysis (sequencing and bioinformatics)
- **Lymphoma Data Hub**: cloud computing platform for large-scale data analysis

#### ECOSYSTEM

LYSARC and LYSA occupy an essential and recognized position in the national and international ecosystem of lymphoma research.

- **Close collaboration** with all stakeholders involved in lymphoma and CLL-WM research worldwide, including hospitals, universities, research organizations, clinical research groups, Cooperative Oncology Groups (INCa-certified), academic societies, health authorities, patient associations...

**Non-exhaustive list of our partners:** AMC Medical Research BV, Centre Henri Becquerel, CNRS-SCTD, FILO (French Innovative Leukemia Organization), FIL (Fondazione Italiana Linfomi), GELTAMO (Grupo Español de Linfomas y Trasplante de Médula Ósea), EORTC (European Organisation for Research and Treatment of Cancer), GLA (German Lymphoma Alliance), HOVON (Stichting Hemato-Oncologie voor Volwassenen Nederland), IELSG (International Extranodal Lymphoma Study Group), IFLY (Institute for Follicular Lymphoma Innovation), IFM (Intergroupe Francophone du Myélome), INSERM (French National Institute of Health and Medical Research), INCa (French National Cancer Institute), Institut Necker, Klinikum der Universität München, MCL Network, Molecular Partners AG, Saarland University, University of Bordeaux, Claude Bernard University, University of Montpellier...

- **Co-founding members of ELI (The European Lymphoma Institute)**, which brings together Europe's leading lymphoma specialists in an institute dedicated to research, training, and education on this disease.



# 02 THE LYSA

**THE LYSA (The Lymphoma Study Association)**  
The LYSA is a leading academic cooperative group dedicated to clinical research on lymphomas and CLL-WM (Chronic Lymphocytic Leukemia - Waldenström's Macroglobulinemia). It was formed in 2012 from the merger of pioneering groups active since the 1980s-1990s, and it designs and leads major clinical studies to advance treatment strategies. Its scientific expertise is strengthened by the operational support of LYSARC, its dedicated clinical research center. Together, LYSA and LYSARC are certified as a "Cooperative Oncology Group" by the French National Cancer Institute (INCa).

## MISSIONS

The LYSA brings together experts in lymphomas and CLL/MW to drive clinical research forward, improve patient care, and foster awareness. As a major player in the field, LYSA plays a key role in therapeutic innovation and large-scale medical education.



Organizing a network of clinical research experts in lymphomas and CLL-WM



Providing research resources and infrastructure



Designing and conduct clinical protocols at all disease stages



Supporting the work of its affiliated care centers



Promoting education and professional training



Assessing new treatment approaches and care pathways



Serving as a recognized interlocutor for national and international agencies, regulatory bodies, and scientific societies



Facilitating translational research, linking experimental labs with patient-focused clinical studies



Disseminating research findings through peer-reviewed journals and present at major conferences



**500** lymphoma and CLL/MW specialists involved as of 2024

**96** care centers active in clinical studies between 2022 and 2024 (all studies combined)

**3 countries** represented:  
France, Belgium, Portugal



## COMMITMENTS

Independence and transparency are central to LYSA's commitments, ensuring the rigor and excellence of its work.

- Independence:** As a non-profit organization (governed by the French 1901 Law), LYSA conducts its research autonomously, free from the influence of public or private entities. It affirms this commitment through its ratification of the Independence Charter of Cooperative Oncology Groups.

- Transparency:** LYSA ensures clear and accessible communication with all its stakeholders — public institutions supporting its activities, patients involved in its trials, the scientific community, and members of its network.

## ORGANIZATIONAL STRUCTURE

LYSA operates through the collective contribution of its active members, its **Board of Directors**, **Scientific Council**, and **Specialized Scientific Committees**.

### Board of Directors, Elected in October 2022

President  
**Franck Morschhauser**

Treasurer  
**Corinne Haïoun**

#### Executive Committee Members

Marc André - Guillaume Cartron - Olivier Casasnovas - Marie-Hélène Delfau-Larue - Hervé Ghesquières - Corinne Haïoun - Roch Houot - Fabrice Jardin - Camille Laurent - Steven Le Gouill - Franck Morschhauser - Catherine Thieblemont

**Members of the Board of Directors:** Marc André - Caroline Besson - Françoise Bodere - Krime Bouabdallah - Guillaume Cartron - Olivier Casasnovas - Sylvain Choquet - Gandhi Damaj - Marie-Hélène Delfau-Larue - Luc-Matthieu Fornecker - Thomas Gatinne - Philippe Gaulard - Hervé Ghesquières - Rémy Gressin - Corinne Haïoun - Olivier Hermine - Roch Houot - Jean-Philippe Jais - Fabrice Jardin - Youlia Kirova - Camille Laurent - Steven Le Gouill - Thierry Molina - Franck Morschhauser - Vincent Ribrag - Karin Tarte - Catherine Thieblemont - Olivier Tournilhac - Alexandra Traverse-Glehen - Luc Xerri - Loïc Ysebaert

### Scientific Council, Appointed in October 2022 by the Board of Directors

President  
**Camille Laurent**

Vice-Presidents  
**Emmanuel Bachy - François Lemonnier**

#### Executive Members of the Scientific Council

Emmanuel Bachy - Christophe Bonnet - Sylvain Carras - Anne-Ségolène Cottreau - Charles Herbaux - Camille Laurent - François Lemonnier - Cédric Rossi - Clémentine Sarkozy - Benoît Tessoulin

**Scientific Council Members:** Yassine Al Tabaa - Marion Alcantara - Sandy Amorim - Emmanuel Bachy - Marie-Christine Bene - Sophie Bernard - Côme Bomnier - Christophe Bonnet - Antonin Bouroumeau - Julien Broseus - Julie Bruneau - Vincent Camus - Sylvain Carras - Morgane Cheminant - Anne-Ségolène Cottreau - Lucile Couronné - Gilles Crochet - Virginie de Wilde - Bénédicte Deau-Fischer - Roberta di Blasi - Eric Durot - Pierre Feugier - Marie Gomes da Silva - Romain Guéze - Charles Herbaux - Salim Kanoun - François Lemonnier - Marie Maerevoet - Guillaume Manson - Laurent Martin - Charline Moulin - Marie-Christine Ngrabacu - Cédric Rossi - Mikaël Roussel - Clémentine Sarkozy - David Sibon - Carole Soussain - Pierre Sujobert - Benoît Tessoulin - Eric Van Den Neste

### Scientific committees and their leads

Committee theme	Committee leads
Diffuse large B-Cell lymphoma	Roch Houot, Fabrice Jardin
T-Cell Lymphoma	Gandhi Damaj, Laurence de Leval, Olivier Tournilhac
Follicular and Other Indolent Lymphomas	Guillaume Cartron, Franck Morschhauser, Catherine Thieblemont
Hodgkin Lymphoma	Marc André, Hervé Ghesquières
Mantle Cell Lymphoma	Morgane Cheminant, Olivier Hermine, Steven Le Gouill



## A STRONG COMMITMENT TO YOUNG MEMBERS

The vitality of LYSA is built on the continual integration of new talent. To support this renewal, the cooperative group has implemented a proactive approach encouraging the active participation of young members in studies. This strategy allows them to become fully involved in research and contribute to the advancement of knowledge on lymphomas.

### Interviews with Our Young Members



**”** I am delighted and enthusiastic to take part in this collective journey as a young member of LYSA-LYSARC. I would like to express my gratitude for the trust placed in me and for the opportunity to work on the DESCAR-T project. This experience has immersed me in the heart of lymphoma research while benefiting from a multigenerational environment that promotes exchange and mutual learning. The mentoring duo format enriched our collaboration, enabling us to tackle projects with confidence and energy. I am particularly impressed by the group's commitment to developing high-quality clinical trials and the importance given to core biological data.

Dr. Nicolas Gower,  
Department of Hematology,  
Lille University Hospital (CHU Lille)



**”** The field of lymphomas and other lymphoid malignancies is evolving rapidly, both in terms of fundamental knowledge and in major therapeutic breakthroughs of recent years. LYSA has established itself as a key player in research in this field. That is why I wanted to fully invest in the group by contributing my expertise, particularly in genomics. The kindness of members, scientific excellence, and the integration of multidisciplinary contributors – biologists, clinicians, pathologists, researchers, statisticians, project managers, legal experts... – at both national and international levels, create an especially stimulating work environment. This collaborative ecosystem is perfectly aligned with my ambition: to develop and apply innovative biological analysis tools to improve patient care.

Dr. Yannick Le Bris,  
Department of Biological Hematology,  
Nantes University Hospital (CHU Nantes)



**”** I am thrilled to develop my research projects on lymphomas within LYSA. The experience of LYSA's members, the institutional support from LYSA/LYSARC, and the strength of the databases linked to LYSA trials are tremendous springboards that help me advance my work and build a vital network to successfully complete it. I am especially proud to lead the INTENSIFY project in collaboration with Dr. Pierre Sesques – this co-PI role entrusted to young members by LYSA is an incredibly enriching journey. The experience I am gaining through this responsibility is preparing me well for future clinical trials. LYSA plays a significant role in both my professional and personal development!

Dr. Sydney Dubois,  
Department of Hematology, Henri Becquerel Center



**”** I am delighted and grateful, as a resident and young member, to be able to grow within the LYSA group and become engaged with research thanks to high-quality mentorship. My work as part of the DESCAR-T registry has allowed me to actively participate in the study of lymphomas and their current therapeutic challenges, in optimal working conditions – especially thanks to the richness of the registry and the quality of its data. This experience has been a major contribution to my training, offering me an early and concrete view of clinical research.

Dr. Marion Aymard,  
Department of Hematology, Henri-Mondor Hospital



# 03 THE LYSARC

LYSARC – A Center of Expertise in Research  
LYSARC(LymphomaAcademicResearchOrganisation)  
is a leading research structure conducting innovative  
projects on an international scale in the field of  
lymphomas, chronic lymphocytic leukemia (CLL),  
and Waldenström's macroglobulinemia (WM). As  
the largest academic structure in Europe dedicated  
to clinical research on these pathologies, LYSARC  
designs, oversees, and coordinates clinical trials  
with widely recognized expertise. Founded in 2000,  
it plays a central role in implementing the research  
programs of the LYSA group.

## MISSIONS

LYSARC provides a full range of integrated platforms  
and functions dedicated to pathology, biology, and  
imaging for conducting clinical studies. Its mission is  
to produce **high-quality data** to enhance scientific  
understanding in the diagnosis, treatment, and care of  
patients with lymphoma and CLL-WM.

## COMMITMENTS

**Independence and transparency** are core principles  
guiding LYSARC's operations, ensuring the reliability  
and excellence of its activities.

- **Independence:** As a non-profit organization (under  
the French Law of 1901), LYSARC conducts its  
research operations with full autonomy, free from  
influence by public or private entities.
- **Transparency:** LYSARC is committed to clear and  
rigorous communication with all its stakeholders —  
public institutions supporting its work, patients  
involved in its studies, the scientific community,  
and its organizational members.

## CORE VALUES

At the heart of LYSARC are essential values that  
drive each team member and ensure excellence and  
integrity in all research activities. These fundamental  
principles underpin its commitment to innovation and  
the fight against lymphomas.



### ENGAGEMENT

"Acting in the interest of patients to enable  
ever more effective prevention and therapies  
against lymphomas and CLL-WM."



### INTEGRITY

"Being authentic, honest,  
and fair with ourselves and others."

**171 employees** as of December 31, 2024 (permanent, fixed-term, and apprentices)

Average workforce in 2024: **167 employees**

## #1 academic structure in Europe dedicated to lymphoma research

LYSARC promotes and supports research initiatives, and has specialized platforms  
in Anatomical pathology, biology and imaging. Every year, it pilots and coordinates  
numerous clinical trials (phases I to IV), as well as non-interventional  
and data re-use studies.




LYSARC is a key expert in research, ensuring the management  
of innovative projects on an international scale.

- **Phase I to IV clinical trials**
- **Non-interventional studies and registries**
- **Data reuse studies (DRS)**

LYSARC is an essential research structure ensuring  
the implementation **of innovative international projects.**

## ORGANIZATIONAL STRUCTURE

The LYSARC brings together all the necessary expertise for conducting research projects on lymphomas:  
operational resources (Clinical Operations and Platforms), cross-functional departments (General Services,  
Finance/Purchasing, Human Resources, Legal, Information Systems, Communication), and Quality Assurance &  
Regulatory Affairs. Governance is ensured by its President, Prof. Franck Morschhauser, and its Chief Executive  
Officer, Florence Agostino-Etchetto, supported by an Executive Committee.






# 04 Looking back on 2024

Each year, the LYSA-LYSARC activity report highlights a selection of the intergroup's key achievements. In 2024, two major projects emerged in follicular lymphoma: BIDIFLY and MorningLyte. The momentum extends well beyond these flagship initiatives: multiple scientific advances, structural developments, fruitful collaborations among researchers, and the success of the 8th LYSA Days. The committed support of donors and other charitable initiatives must also be acknowledged. Finally, this report attests to the exceptional influence of the intergroup: at conferences, in leading scientific journals, and in both specialized and mainstream media.

## 01 Launch of Two Major Projects in Follicular Lymphoma

### 1 HARNESSING ARTIFICIAL INTELLIGENCE WITH THE BIDIFLY PROGRAM



**BIDIFLY = Biological and Imaging Data Integration for Follicular Lymphoma research**

#### 2024 HIGHLIGHTS

**MARCH 2024**  
Launch conference

**MAY 2024**  
Announcement of additional funding

The BIDIFLY program won the MESSIDORE call for proposals (Methodology for Innovative Clinical Trials, Devices, Tools, and Research Using Health Data and Biobanks). This call is an initiative from INSERM, part of its strategic collaborative health research program supported by the Ministry of Health and Prevention. The additional grant of €1.4 million strengthens the project's ambitions, bringing the total budget to €9 million.

**PROGRAM OVERVIEW:**

- > Use of artificial intelligence in follicular lymphoma
- > Analyses integrating large datasets from clinical data, imaging, and molecular biology
- > Involvement of world-renowned scientists and clinicians

**DURATION:**  
4 years

**MAJOR OBJECTIVES:**

- > Better characterize this heterogeneous disease
- > Identify early biomarkers for patients at high risk of relapse
- > Provide insights for optimizing therapeutic targets

**TOTAL BUDGET:**  
€9 million

**Project Originators**

- LYSA/LYSARC
- IFLI (Institute for Follicular Lymphoma Innovation)

**Key Partners**

- Institut Carnot CALYM
- INSERM
- Institut Curie
- Institut Paoli-Calmettes
- University Hospital of Rennes
- University Hospital of Toulouse

“The LYSA-LYSARC intergroup was pleased to launch the innovative BIDIFLY program alongside its partners at a symbolic venue: ParisSanté Campus, the digital health development center in the heart of Paris. A press conference was held for the occasion, and no fewer than 80 people gathered to learn more about the project.

Aurélié ONNIS  
Head of Communications

# 2

## MORNINGLYTE PIVOTAL STUDY IN FIRST-LINE TREATMENT

**Mosunetuzumab**  
CD20xCD3 bispecific antibody  
INNOVATIVE THERAPEUTIC CLASS  
Targets B-cell lymphoma cells  
Recruits T immune cells  
+  
**Lénalidomide**  
Immunomodulatory agent

versus  
**Standard immunochemotherapy**  
Anti-CD20 monoclonal antibody + chemotherapy

#### 2024 HIGHLIGHTS

**MAY 2024**  
Official launch

**JUNE 2024**  
First randomized patient

**NOVEMBER 2024**  
Progress meeting with industry partners

”



The LYSA group has ensured and maintained strong continuity in follicular lymphoma research over the past 40 years. Following the PRIMA and RELEVANCE studies led by LYSA, the implementation of bispecific antibodies as first-line treatment to replace anti-CD20 monoclonal antibodies is the most logical and conceptually promising next step based on current knowledge. MorningLyte is the first academic study co-designed with GLA in follicular lymphoma, and LYSA is very pleased to also benefit from the expertise of GELTAMO, AGMT, SAKK, and our Japanese colleagues to successfully carry out this endeavor.

Franck Morschhauser  
President of LYSA

”



MorningLyte will be one of the most important follicular lymphoma studies in recent years, with a realistic potential to change our standard of care for first-line treatment roughly 20 years after the introduction of immunochemotherapy. An academic study of this magnitude requires joint efforts at both the European and international levels. We at GLA are proud to partner with LYSA/LYSARC to lead this pivotal study, together with our Austrian, Spanish, Swiss, and Japanese colleagues.

Christian Buske  
Chair of the “Indolent Lymphoma” working group  
Former President of the GLA

#### First-Line Treatment

**790+** adult patients  
18 years or older, no age limit

#### 8 countries

France, Belgium, Portugal, Germany, Spain, Switzerland, Japan, and Austria

#### 10 years

**3 years** of enrollment  
+ **7 years** minimum follow-up



#### STUDY OVERVIEW:

> Phase III, randomized, open, international, multicenter study evaluating the efficacy and safety of mosunetuzumab + lenalidomide versus an anti-CD20 monoclonal antibody + chemotherapy in previously untreated patients with follicular lymphoma

#### HIGH EXPECTATIONS:

> Offer a “chemotherapy-free” alternative with the hope of reducing relapses and improving patients’ quality of life  
> Redefine the standard of care in first-line follicular lymphoma treatment?

#### 5 Academic Partners

- LYSA/LYSARC
- GLA (German Lymphoma Alliance)
- GELTAMO (Spanish Group for Lymphomas and Autologous Bone Marrow Transplant)
- SAKK (Swiss Group for Clinical Cancer Research)
- AGMT (Austrian Group for Medical Tumor Therapy)

#### 2 Industry Partners

- Roche
- Chugai

## 02 Multiple Other Scientific Advances Worth Noting

The LYSA-LYSARC Intergroup can legitimately take pride in having built, over the years, a rich and ever-evolving scientific activity. The 2024 activity is a concrete demonstration of this, with a wide variety of projects and collective achievements (a full list of projects is available in the scientific report, page 30).



### FOCUS ON 3 MAJOR AREAS

## 1 STRONG CLINICAL ACTIVITY FOR PATIENTS WITH RELAPSE/ TREATMENT FAILURE

### > LAUNCH OF THE CARMOD STUDY WITH BRISTOL MYERS SQUIBB (BMS)

**Study type:** Phase II  
**Treatment under study:** Golcadomide, a compound in the CELMoD family (cereblon E3 ligase modulators)  
**Target lymphoma:** Aggressive large B-cell lymphoma with high risk of relapse  
**Study objective:** Evaluate the efficacy and tolerance of golcadomide administered after anti-CD19 CAR-T cell infusion in patients with relapsed or refractory aggressive large B-cell lymphoma at high risk of relapse  
**Key updates:**

- > Study launch in July 2024
- > Recruitment of approximately 65 patients in France
- > Patient follow-up for a minimum of 2 years

### > FINALIZATION PHASE OF THE VALYM STUDY WITH DAIICHI SANKYO

**Study type:** Phase II  
**Treatment under study:** Valemetostat tosylate, an EZH1/2 inhibitor  
**Target lymphoma:** Relapsed or refractory B-cell lymphoma  
**Study objective:** Evaluate the efficacy and tolerance of valemetostat tosylate in patients with relapsed or refractory B-cell lymphoma  
**Key updates:**

- > Progress meeting with Daiichi Sankyo in 2024
- > First results presented at a 2024 congress
- > Additional publications to follow in congresses and scientific journals



*"Patients with aggressive B-cell lymphomas and large tumor burdens have a lower probability of responding to CAR-T cell therapy. We believe that the immunomodulatory properties of golcadomide will help improve CAR-T cell effectiveness in the highest-risk patients."*

**Dr. Gabriel Brisou**  
 Onco-hematologist,  
 Institut Paoli-Calmettes, Marseille



*"This major collaborative project is nearing completion. However, the journey continues for certain patients still on Valemetostat treatment, who are continuing to benefit clinically. We are working with the Daiichi Sankyo team to find solutions to ensure these patients can continue treatment in the best possible conditions."*

**Prof. Emmanuel Bachy,**  
 Hematologist, Lyon Sud Hospital Center

### > COMPLETION OF THE BICAR STUDY WITH ROCHE

**Study type:** Phase II  
**Treatment under study:** Glofitamab, a CD20xCD3 bispecific antibody  
**Target lymphoma:** Large B-cell lymphoma after CAR-T cell treatment failure  
**Study objective:** Evaluate the efficacy of glofitamab, a CD3xCD20 bispecific antibody, in patients relapsing after CAR-T cell therapy  
**Key updates:**

- > Follow-up of 67 patients over 3 years (2021-2024)
- > Press release issued
- > Results presented at a 2024 congress
- > Additional valorizations to come



*"Glofitamab already brings important hope to patients. These results support the relevance of the concept of in vivo immunomodulation of CAR-T cell and/or residual T-cell activity. They already allow us to envision new applications of this therapeutic concept in relapses occurring after CAR-T cell administration."*

**Prof. Guillaume Cartron,**  
 Hematologist, Montpellier University Hospital,  
 Lead Investigator of the BICAR study

 [Read the press release](#)

## 2 LEADING ROLE IN RESEARCH ON PERIPHERAL T-CELL LYMPHOMAS

### > DEVELOPMENT OF AN INNOVATIVE METHODOLOGY WITH THE PLATFORM STUDY

**An initiative of the LYSA/LYSARC intergroup for patients with peripheral T-cell lymphomas**

- > Representing 5-10% of lymphomas diagnosed in France (~600 new cases/year)
- > Aggressive lymphomas associated with poor prognosis
- > Heterogeneous diseases with about thirty distinct subtypes
- > Limited scientific progress to date and few studies implemented

**Creation of a platform trial to generate proof-of-concept data on the relevance of certain treatments** (monotherapy or combinations)

- > Adaptive trial, with no pre-set end date, evolving through the addition or discontinuation of treatment arms based on predefined rules
- > Multiple sub-studies carried out simultaneously or sequentially
- > Each arm classified as Phase I, I/II, or II

**Examples of challenges met, demonstrating operational innovation in this launch:**

- > Definition of a "master protocol" including shared elements across all sub-studies (inclusion/exclusion criteria, assessments, etc.)
- > Preparation of "sub-protocols" with specific features for each sub-study (IMP, stricter inclusion criteria, additional assessments, etc.)
- > Structuring of a complex database allowing both global tracking and differentiation between sub-studies

**Additional complementary actions:**

- > Consultation with the ANSM's Innovation and Guidance Office (GIO)
- > Consultation with patient association ELLyE (Ensemble Leucémie Lymphomes Espoir) as part of the PRECAP project (Patient Association Participation in Clinical Trials and Research)

## 3 SIGNIFICANT CONTRIBUTION FROM REAL-WORLD DATA REGISTRIES

### > DESCAR-T: THE FRENCH REGISTRY OF ADULT AND PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES ELIGIBLE FOR CAR-T CELL THERAPY



- > Inclusion period extended beyond the initial end date of 2024
- > New findings presented at congresses and published in scientific journals

#### DESCAR-T'S role in the launch of UNITC, the first national consortium for cell and gene therapy research

The DESCAR-T registry is one of the founding entities of this promising consortium, resulting from a call for proposals by the French National Cancer Institute (INCa) to label a national research network for CAR-T cell and other innovative gene therapies in oncology. Objectives: Uniting research teams to create synergies, representing researchers before health authorities and funding bodies, supporting and facilitating research through operational, financial, and strategic backing.

### > REALYSA: MULTICENTER REAL-WORLD FRENCH COHORT OF ADULT PATIENTS WITH LYMPHOMA

- > Follow-up of inclusions completed between 2018 and 2023, continuing through 2028
- > New findings presented at congresses and published in scientific journals



#### Creation of an EXPLANATORY VIDEO FOR AND WITH PATIENTS to improve participation in epidemiological studies

This video, created at the initiative of REALYSA's patient partner group, provides clear, accessible information on data collection and its importance for research. It can easily be adapted for other similar studies.

**Watch the video**





## 03 Structural Actions for Strengthened Impact

The LYSA-LYSARC intergroup continues its commitment to excellence by carrying out, each year, major structuring projects to strengthen its foundations and build the future. At LYSARC, this ambition was notably realized in 2024 through the renewal of ISO 9001 quality certification and the digital transformation project initiated by the legal team. As for LYSA, it has added a new commission.

### FOCUS ON 3 STRUCTURING ACTIONS IN 2024

#### CREATION OF A NEW LYSA COMMISSION

In the interest of scientific coherence and operational efficiency, LYSA created in February 2024 a new commission specifically dedicated to chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia (WM). This major development marks an important step in the structuring of clinical research on lymphoid malignancies in France.

This initiative is part of a convergence dynamic driven by the FILO CLL/WM committee, with the objective of unifying research efforts on diseases that share close biological, clinical, and therapeutic characteristics. Until now, French clinical research on lymphoid malignancies was organized around two major historical groups:

- > on the one hand, malignant non-Hodgkin lymphomas and Hodgkin's disease, led by GELA and GOELAMS, which merged in 2012 to form LYSA,
- > on the other hand, CLL and WM, structured around the French CLL/WM Group and GOELAMS, and later integrated into the FILO group.

The rapid evolution of the therapeutic landscape, with the arrival of innovative treatments often shared by these diseases, now makes an integrated and collaborative approach essential. The creation of this CLL/WM commission within LYSA meets this requirement, while also strengthening the competitiveness of French research on an international scale.

This strategic alignment aims to support the development of large-scale clinical and biological trials, while maintaining a high level of scientific rigor. It paves the way for greater synergy between clinicians and researchers, for the benefit of optimized care for patients affected by these chronic hematological malignancies.

Access the press release



*"It is with great pleasure that we welcome all the investigators from the FILO CLL/WM committee, who have collectively decided to join us within LYSA to carry out their upcoming studies and thereby help consolidate French projects on lymphoid malignancies."*

**Franck Morschhauser**  
President of LYSA

#### RENEWAL OF THE ISO 9001 QUALITY CERTIFICATION

The ISO 9001 quality certification is granted by an accredited independent body for a renewable period of three years. The renewal of this certification for LYSARC's research activities was confirmed in 2024. It reflects the strong commitment to a rigorous Quality Management System, fully aligned with Good Clinical Practice (GCP).

#### DIGITAL TRANSFORMATION PROJECT INITIATED BY THE LEGAL DEPARTMENT

The legal team has launched a digital transformation project to optimize its organization, with the goal of improving efficiency and better supporting the launch of innovative projects. It has already adopted the legal intelligence platform "Doctrine," which facilitates monitoring, searching, and analyzing available legal information.

The next step is the implementation of a Contract Lifecycle Management (CLM) tool to further structure the setup and monitoring of contracts. In this context, the Legal Department took part in the "Rendez-vous des Transformations du Droit" congress in Paris in November 2024. This key event provided an opportunity to meet major players in the field and strengthen the team's knowledge to ensure the project's success.

## 04 Successful Synergies Between Researchers in France and Internationally

The LYSA-LYSARC intergroup creates and maintains strong relationships with numerous oncology research stakeholders in France and internationally. The year 2024 perfectly illustrates this with two highlights: the signing of a new partnership with a consortium of international experts and the celebration of the 15th anniversary of the Cooperative Groups in Oncology (GCO) network, of which the LYSA-LYSARC intergroup is a founding member.

### FOCUS ON 2 HIGHLIGHTS

#### NEW PARTNERSHIP WITH THE HOLISTIC CONSORTIUM

In 2024, the LYSA-LYSARC intergroup signed a strategic partnership with HoLISTIC (Hodgkin Lymphoma International Study for Individual Care), an international consortium bringing together more than 80 experts to advance knowledge on Hodgkin lymphoma. Objectives: collaboration among experts, data sharing, and implementation of joint research projects.

”



*"This partnership marks an important milestone in our commitment to fight Hodgkin lymphoma. It will notably allow us to use a harmonized database, including thousands of patients, to advance research in personalized medicine."*

**Prof. Cédric Rossi, Hematologist**  
University Hospital of Dijon

Access the HoLISTIC consortium website



#### 15 YEARS OF THE COOPERATIVE GROUPS IN ONCOLOGY (GCO) NETWORK

The LYSA-LYSARC intergroup is one of the founding members of the Cooperative Groups in Oncology (GCO) network, which celebrated its fifteenth anniversary in 2024.

This is a major milestone for a network committed to promoting and enhancing clinical research conducted by the GCOs.

Access the GCO network website



#### Organization of an inter-GCO webinar for patients and their families

In October 2024, the GCO network launched a major initiative to improve the patient care pathway: a free webinar designed for patients and their families, on the theme *"The role of supportive care in the cancer care pathway: how to ensure its accessibility and quality?"*.






## 05 8th LYSA Days – A Success

LYSA successfully renewed the momentum of its signature event, “Les Journées du LYSA,” to share the latest advances in lymphoma research. The 8th edition brought together more than 550 participants in Tours from January 31 to February 2, 2024. The program featured high-quality presentations and enriching discussions.



“I warmly thank the many LYSA speakers and the prestigious international presenters who agreed to share their work during these Journées, as well as all the LYSARC and CALYM teams for their enthusiasm and major contributions to our successes. Thanks also to all the members of the group for their participation and contributions to the various commissions, to the Scientific Committee, which once again put together an enticing program, to our loyal sponsors, and to everyone who contributed to the success of these 8th Journées. I would also like to thank Emmanuel Gyan and his team, who welcomed us to the beautiful city of Tours.”

Prof. Franck Morschhauser  
President of LYSA



## 06 Tribute to Donors and Other Solidarity Initiatives

Many individuals and companies support the fight against lymphomas through their donations to the LYSA Endowment Fund. The LYSA/LYSARC intergroup wishes to acknowledge all initiatives, in whatever form, that directly or indirectly help improve the lives of patients affected by the disease.

### FOCUS ON 2 REMARKABLE INITIATIVES

#### LES FOULÉES DE CHASSE-SUR-RHÔNE

For 15 years now, the association SANG POUR SANG SPORT has organized the event “Les Foulées de Chasse-sur-Rhône,” a charity run in support of the fight against lymphomas. Around twenty members of the LYSARC team participated in the 2024 edition, showing strong solidarity—and even landing two spots on the podium!

The event registered more than 400 entries across three proposed routes: 5, 10, or 15 kilometers. All proceeds contributed to funding a reathletization program for adolescents with lymphoma in partnership with Lyon Sud Hospital.

“Every step counts in the fight against lymphomas. This sporty and supportive morning was a wonderful occasion to remind everyone of that! And after the effort, the comfort! The warm refreshment station was the perfect moment to celebrate our successes.”

Marguerite Fournier  
Biostatistician, LYSARC

Information about the race and the association's projects supporting the fight against lymphomas



#### BRI'FIT EVENT

For the sixth consecutive year, the Kidsport association renewed its support for the LYSA Endowment Fund by donating all proceeds from its annual fitness event: BRI'FIT EVENT. Nearly 50 participants gathered in Briançon in the Alps, with a team of five coaches especially coming from Lyon and Turin.

LYSA warmly thanks all those involved in the BRI'FIT EVENT, especially Brigida Tolomeo, who initiated the project. Thanks also go to the local merchants and firefighters of Briançon, who made additional donations to further strengthen the success of this charitable event.

“We were able to donate more than 2,000 euros to support LYSA's lymphoma research programs. It's a great achievement for a cause that is especially close to my heart! See you in 2025 for the next edition.”

Brigida Tolomeo  
Founder of the Kidsport Association

Information about the LYSA Endowment Fund





## 07 Exceptional Visibility at Conferences

In 2024, the LYSA-LYSARC intergroup participated in more than 20 scientific congresses and meetings in France and internationally. This exceptional engagement enabled high-quality exchanges, fruitful knowledge sharing, and more than 70 valorizations of LYSA-LYSARC's work (complete list of posters and oral presentations available in the appendix on page 44).



## STRONG AND NOTICEABLE PRESENCE AT 3 LEADING CONGRESSES

The year 2024 showcased LYSA-LYSARC's research at three major hematology events:

the congress of the Société Française d'Hématologie (SFH), the European Hematology Association (EHA) congress, and the American Society of Hematology (ASH) congress.

In total, LYSA-LYSARC's work was featured in over 50 valorizations across these three flagship congresses. Among the highlighted projects were: DESCAR-T, REALYSA, ALYCANTE, LYMA, VALYM, BICAR, POLARIX, and more.

At the SFH congress, LYSA also played an active role by organizing two sessions: A Cooperative Groups session featuring three presentations on mantle cell lymphoma, and A Spotlight session with three presentations on the theme: "The postdoctoral journey in the USA: what scientific and personal insights?"

In addition, during this congress, the dedicated ARC/TEC (Clinical Research Associates/Technicians) day was once again organized by LYSARC in collaboration with the hematology cooperative groups (ALFA, FILO, GFM, GRAALL, IFM, LYSA, SFGM-TC).



Dr. Clémentine Sarkozy, MD, PhD, Hematologist, Institut Curie



## 08 Dense and Recognized Scientific Production

The LYSA-LYSARC intergroup reaffirmed its leading role in lymphoma research by generating 51 scientific publications in 2024 (complete list available in the appendix on page 38). The quality and impact of this research were recognized by leading journals such as Nature, Blood, European Journal of Cancer, and Hematological Oncology.

**nature**

### PROMISING PATHWAY IN HODGKIN LYMPHOMA


Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling – S. K. Alig

#### Excerpt from the publication:

"These findings support the usefulness of noninvasive strategies for genotyping and dynamic monitoring of classical Hodgkin lymphoma (cHL), as well as for the identification of distinct molecular subtypes with diagnostic, prognostic, and therapeutic potential."



### FOCUS ON 8 MAJOR PUBLICATIONS



### LEVERAGING REAL-WORLD DATA FROM THE REALYSA REGISTRY IN MARGINAL ZONE LYMPHOMA

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study – C. Bommier

#### Excerpt from the publication:

"This nationwide French study provided, for the first time, prospective data on the clinical characteristics, initial management, and treatment response of patients with marginal zone lymphoma."



### REALYSA REGISTRY INSIGHTS ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort – A. Anota

#### Excerpt from the publication:

"A comprehensive analysis was conducted to describe the health-related quality of life (HRQoL) profile of newly diagnosed patients with various types of lymphomas. Our data may help improve interpretation of HRQoL results in future studies using the lymphoma-specific questionnaires recently validated by the EORTC (European Organisation for Research and Treatment of Cancer)."



### POSITIVE RESULTS FOR THE PVAB PROTOCOL IN HODGKIN LYMPHOMA

The Phase II LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients – H. Ghesquière

#### Excerpt from the publication:

"In the absence of new drugs, PVAB could be considered a bleomycin-free therapeutic regimen for older patients with Hodgkin lymphoma who are in good condition based on geriatric assessments."



### LONG-TERM RESULTS FROM THE LYMA-101 STUDY IN MANTLE CELL LYMPHOMA

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma – C. Sarkozy

#### Excerpt from the publication:

"Obinutuzumab can be safely used in combination with chemotherapy and as maintenance after autologous stem cell transplantation as first-line treatment. Compared with rituximab, obinutuzumab offers better disease control without added toxicity."



### EFFICACY OF CAR-T CELL THERAPY IN WALDENSTRÖM'S MACROGLOBULINEMIA

High efficacy of CD19 CAR-T cells in patients with transformed Waldenström macroglobulinemia – E. Durot

#### Excerpt from the publication:

"We report here the first series of transformed Waldenström macroglobulinemia cases treated with CAR-T cells, demonstrating not only high efficacy but also no unexpected toxicities."



### MOLECULAR SUBTYPING OF FOLLICULAR LYMPHOMA BASED ON THE RELEVANCE STUDY

Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance – C. Laurent

#### Excerpt from the publication:

"Immunohistochemistry can be routinely used to identify follicular lymphoma patients with memory B-cell profiles, who have poorer progression-free survival. These patients could benefit from treatments other than chemotherapy."



### CONFIRMED EFFICACY OF CAR-T CELLS AFTER BISPECIFIC ANTIBODY THERAPY

Efficacy of CAR-T cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma – G. Crochet

#### Excerpt from the publication:

"These findings are clinically relevant, particularly given the increasing use of bispecific antibodies in earlier lines of treatment."





# 09 Visibility in Specialized and General Media

LYSA-LYSARC's news enjoyed strong media coverage in 2024. Several press releases were picked up by specialist media outlets, including APMnews and La Gazette DIAG & SANTÉ. Major mainstream newspapers such as Le Monde and Le Figaro also spotlighted key intergroup projects.

## FEATURED ARTICLES IN SPECIALIZED PRESS



MYPHARMA EDITIONS – 27/03/2024

LYSARC and Roche: promising success of a bispecific antibody shown in a French study

Read the article



HEALTH & TECH INTELLIGENCE  
29/03/2024

AI: launch of Bidifly, a €9M research project to improve treatment of follicular lymphoma

Read the article



Read the article



APMNEWS – 05/04/2024

Interest in bispecific antibody glofitamab in lymphomas resistant to CAR-T cell therapy (French study)



Read the article



LA GAZETTE DIAG & SANTÉ – 13/04/2024

LYSARC and Roche – Results from the BICAR study

Immunomodulation in patients with relapsed lymphoma after CAR-T cell therapy: the promising success of a bispecific antibody (Glofitamab) demonstrated in a French study



LA GAZETTE DU LABORATOIRE/  
AFRIQUE – 17/10/2024

Launch of the international clinical study MorningLyte

Read the article



REVUE ONKO.fr

REVUE ONKO – 22/10/2024

Follicular lymphoma: launch of an international clinical study

Read the article



## ARTICLES IN GENERAL PRESS

Le Monde

LE MONDE – 29/04/2024

Cancer: the CAR-T cell saga – the tumor “Terminators”

Read the article



LE FIGARO

LE FIGARO – 12/05/2024

CAR-T cells: the “living drugs” revolutionizing cancer care

Read the article



LA MONTAGNE

LA MONTAGNE – 15/09/2024

The Clermont-Ferrand University Hospital: a leading expert center in lymphoma research in France

Read the article



LE PROGRÈS

LE PROGRÈS – 17/09/2024

Extensive real-world study: 6,000 patients followed over nine years

Read the article



## LYSA-LYSARC PUBLIC STATEMENTS

### FEBRUARY 2024

LYSA-LYSARC Press Release  
LYSA–FILO Partnership

LYSA launches a new committee dedicated to chronic lymphocytic leukemia and Waldenström's macroglobulinemia

Access the press release



### MARCH 2024

LYSA-LYSARC Press Release  
BICAR Study

Immunomodulation in patients with relapsed lymphoma after CAR-T cell therapy: promising success of a bispecific antibody (Glofitamab) demonstrated in a French study

Access the press release



LYSA-LYSARC / IFLI Press Conference  
BIDIFLY Project

Launch of the BIDIFLY project, a research program in follicular lymphoma

See details on page 16

### MAY 2024

Institut Curie Press Release  
BIDIFLY Project

LYSA-LYSARC's BIDIFLY project, coordinated by Institut Curie, receives €1.4M to advance understanding and treatment of follicular lymphoma

Access the press release



### OCTOBER 2024

LYSA-LYSARC Press Release  
MorningLyte Study

LYSA and GLA launch MorningLyte, a randomized phase III international clinical trial comparing a treatment combining a CD20xCD3 T-cell engaging bispecific antibody and lenalidomide versus standard immunochemotherapy in patients with previously untreated follicular lymphoma

Access the press release



# 05 2024 Scientific Report

A Word from **Prof. Camille Laurent**,  
President of the Scientific Council and member  
Board of Directors



The year 2024 reaffirmed the scientific vitality of our intergroup and our leading role in lymphoma research.

The success of the 8<sup>th</sup> LYSA Annual Meeting at the beginning of the year was a shining example of this. More than 550 attendees gathered in Tours around a rich and stimulating program, made possible by the dedication of the LYSA committees and the participation of esteemed speakers. Several clinical studies were showcased alongside a cutting-edge biological program featuring **single-cell molecular studies**, **ctDNA analysis**, and **spatial tissue studies**.

Our scientific production remains at a high level, with **51 articles published**, including notable work in prestigious journals such as Nature and Blood. I would like to highlight the work of my colleague **Dr. Vincent Camus**, lead author of several 2024 publications. Among them, discover this outstanding clinico-biological article in Blood Advances: "*Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5' RACE*."

We should also highlight our **74 congress valorizations**: **44 oral communications** and **30 posters**. Our presence was particularly strong at the three major hematology events organized by the **French Society of Hematology (SFH)**, the **European Hematology Association (EHA)**, and the **American Society of Hematology (ASH)**.

These achievements are the result of **remarkable collective commitment**, which is essential to sustain our activity year-round. The numbers speak for themselves: a portfolio of **29 clinical studies** (RIPH1 and 2) and **6 cohorts** (RIPH3), **84 active investigator sites**, **2,108 patient enrollments**, **114 analysis reports issued**, as well as a portfolio of over **150 data reuse studies**.

2025 promises to be just as dynamic, with the rollout and scaling-up of several projects initiated in 2024.

Three new clinical trials began recruitment in 2024: a **Phase II trial (CARMOD)**, a **Phase III trial (MORNINGLYTE)** and an **observational study (FERTILE)**. In addition, recruitment resumed for the second phase of a **Phase II trial (OASIS)**. The **BIDIFLY program** continues to grow, and we also launched the **INTENSIFY project** in diffuse large B-cell lymphoma, aiming to identify patients at high risk of early relapse through integrative multimodal analyses from our clinical trials.

Looking ahead to 2025, a key highlight will be the **publication of LYSA expert recommendations** for several lymphoid malignancies. The first, dedicated to **primary mediastinal B-cell lymphoma (PMBL)**, will be released in the first quarter of 2025. This will be followed by guidelines for **diffuse large B-cell lymphoma and Hodgkin lymphoma**.

Finally, **new advances will emerge** from the creation of a **new LYSA committee dedicated to chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia (WM)**. The CLL committee of FILO has joined LYSA, bringing our strengths together to advance research on these two diseases.

**In conclusion, 2024 ends on a very positive note and sets the stage for a promising 2025.** On behalf of the LYSA and LYSARC Scientific Council, I want to express our deepest gratitude to all the research stakeholders—scientists, clinicians, clinical research experts, partners, institutions, and especially patients—who make this progress possible.

## 01 Overview of 2024 scientific projects



**35 active projects**


(initiated, recruiting, under follow-up, or completed)

**6 cohorts**

**21 phase II studies**

**8 phase III studies**

### Scientific Dynamism



**8 new project proposals validated in 2024**

- **6 projects** in active preparation in 2024
- **2 projects** set to begin preparation in January 2025

**10 projects open to recruitment**

- **7 interventional studies**
- **3 non-interventional studies**



**14 projects with patients currently in treatment or post-treatment follow-up**

**6 projects nearing completion**

**114 analysis reports issued**

**125 total research valorizations:**

- **51 publications**
- **74 congress valorizations**



## 02 Focus on 3 non-interventional studies in recruitment

### DESCAR-T

National registry of patients with hematologic malignancies eligible for CAR-T cell therapy.

#### > Recruitment in progress

- 5,061 patients treated with this innovative therapy have been enrolled as of December 2024 (since late 2019)
- Enrollment to continue in 2025
- 15-year patient follow-up planned

#### > Data analysis underway, with numerous valorizations already achieved:

- 20 congress valorizations
- 11 published articles
- 13+ ongoing projects in 2024
- 1 completed project

Note: Access to some CAR-T therapies ended in 2024 as early access programs concluded.

### BIA-ALCL

Observational study of ALK-negative anaplastic large cell lymphomas associated with breast implants.

### LYSATOMIC

Characterization of diagnostic, prognostic, and theranostic molecular biomarkers in the clinical management of T-cell (and NK-cell) lymphomas.



Detailed Study Highlights



**HAS**


HAUTE AUTORITÉ DE SANTÉ


Recognized as one of the "data sources usable for responding to requests from the French National Health Authority (HAS)"






# 03 Focus on 7 interventional studies in recruitment


**CARMOD (Phase II)**  
Study of golcadomide after CAR-T cell treatment in patients with relapsed or refractory aggressive large B-cell lymphoma and at high risk of relapse.

**KILT (Phase II)**  
Study of lacutamab with GemOx versus GemOx alone in patients with relapsed or refractory peripheral T-cell lymphoma.

**MARSUN (Phase III)**  
Study of the combination of mosunetuzumab-lenalidomide versus investigator's choice of therapy in patients with relapsed or refractory marginal zone lymphoma.



**MORNINGLYTE (Phase III)**  
Study of mosunetuzumab combined with lenalidomide versus an anti-CD20 monoclonal antibody combined with chemotherapy in patients with untreated follicular lymphoma with a FLIPI score of 2 to 5.


**OASIS II (Phase II)**  
Study evaluating the combination of ibrutinib/anti-CD20/venetoclax in previously untreated patients with mantle cell lymphoma.


**TRANSCRIPT (Phase III)**  
Study aimed at determining whether autologous stem cell transplant reduces disease relapse compared to treatment without transplant.

**VERLEN (Phase II)**  
Study evaluating lenalidomide combined with tafasitamab and rituximab as first-line treatment in patients aged 80 and over with diffuse large B-cell lymphoma.

# 04 Focus on 114 statistical analyses

Overall research activity generated significant momentum, with 114 statistical deliverables in 2024. Nearly half were related to real-world data registries DESCAR-T and REALYSA (52 outputs from these two registries alone).

**114 analysis outputs in total:**



- 29** statistical reports for clinical studies
- 55** reports for data reuse studies (DRS)
- 29** database exports
- 1** long-term follow-up report

# 05 Focus on project ideas

The LYSA/LYSARC intergroup remains fully committed to transforming project ideas into scientific success. The 2024 activity again illustrated this remarkable synergy, with several projects in development and a strong series of projects successfully launched.

**> PROJECTS IN DEVELOPMENT/UNDER CONSTRUCTION IN 2024**  
**4 examples:**  
**CARMAN Study (International Phase III)**  
First-line study in mantle cell lymphoma involving CAR-T cell treatment.  
**CLL18 Study (International Phase III)**  
First European collaborative project in chronic lymphocytic leukemia under the auspices of the GCLLSG (German CLL Study Group).  
**PLATFORM Study (Phase Ib/II)**  
Platform trial evaluating new drugs or combinations for the treatment of relapsed or refractory peripheral T-cell lymphomas. Three treatment arms have already been validated and are expected to open for recruitment in 2025. This is an innovative project addressing a medical unmet need.  
**GLOREL Study (RNIPH)**  
Study established to collect data from patients previously treated with glofitamab under early access.

**> PROJECTS SUCCESSFULLY LAUNCHED**  
**3 studies launched in 2024:**  
**CARMOD Study (Phase II)**  
Study of golcadomide after CAR-T cell treatment in patients with relapsed or refractory aggressive large B-cell lymphoma and at high risk of relapse.  
**MORNINGLYTE Study (Phase III)**  
Study of mosunetuzumab combined with lenalidomide versus an anti-CD20 monoclonal antibody combined with chemotherapy in patients with untreated follicular lymphoma with a FLIPI score of 2 to 5.  
**FERTILE Study (RNIPH)**  
Study on fertility in young women treated with intensive chemotherapy for diffuse large B-cell lymphoma, as part of clinical trials LNH-03 1B, LNH-03 2B, LNH-07 3B, and GAINED.

# 06 Focus on research valorizations

**51 published articles**

**74 congress valorizations**

- > 44** oral communications
- > 30** posters

**LEAD STUDIES**  
**17 total valorizations**

- > 9** published articles
- > 8** congress valorizations

**DATA REUSE STUDIES (DRS)**  
**87 total valorizations**

- > 36** published articles
- > 51** congress valorizations

**OTHER (GUIDELINES, EXPERT OPINIONS, ETC.)**  
**21 total valorizations**

- > 6** published articles
- > 15** congress valorizations

**DESCAR-T**  
**31 total valorizations**

- > 11** published articles
- > 20** congress valorizations

**REALYSA**  
**17 total valorizations**

- > 4** published articles
- > 13** congress valorizations


# 06 LYSA centers and LYSA-LYSARC platforms activities

The scientific vitality of the intergroup is manifested through the activity of the LYSA investigator centers, with more than 2,000 enrollments in 2024. It is also demonstrated by the dynamism of the joint LYSA-LYSARC research platforms, which are essential for conducting clinical studies and data reuse studies : bioinformatics, anatomical pathology (LYSA-P), biopathology (LYSA-BIO), and imaging (LYSA-IM).



## 01 LYSA investigating centers activities

The number of active centers remained generally stable in 2024 compared to 2023 (84 in 2024 vs. 87 centers in 2023). The number of inclusions was high, although it declined (2,108 in 2024 vs. 3,053 in 2023). This decrease is due to the end of inclusions in the REALYSA registry, which occurred in October 2023 and led to a 36% drop in inclusions in observational studies in 2024. Conversely, it is worth noting the 39% increase in clinical trial inclusions, thanks to the launch of several new studies in 2024.

### LOOKING BACK AT THE LAST 3 YEARS:



### FOCUS ON THE YEAR 2024:



## 02 Bioinformatics platform activities

The bioinformatics platform continued its positive momentum in 2024. It participated in eight data reuse study (DRS) projects, a volume comparable to that of 2023. This momentum is strengthened by the ramp-up of the pioneering BIDIFLY program (Biological and Imaging Data Integration for Follicular Lymphoma Research). This trajectory will continue in 2025, driven by the acceleration of BIDIFLY and the management of many other projects (ALKOBS, DLBCL\_EBV+, INTENSIFY...).

### 2024 HIGHLIGHTS

- Involvement in 8 data reuse study (DRS) projects**
  - > The majority of analyses focused on DNA and RNA sequencing
- Ramp-up of the BIDIFLY research program**
  - > Setup of the data storage and analysis environment within the Lymphoma Data Hub, supported by the Carnot CALYM Institute
  - > Launch of the first analyses
  - > Strengthening of the project team with the arrival of a new collaborator
- Notable valorization of completed projects**
  - > X scientific valorizations (3 published articles + X congress valorizations)
  - > **Example of a publication in Blood journal:** the BIO-RELEVANCE project led to a new molecular classification of follicular lymphomas
  - > **Example of a congress presentation at the French Society of Hematology (SFH):** a methodological review of bioinformatic approaches for addressing background noise in ctDNA detection
- Active role in the ecosystem**
  - > Coordination of a collaborative group of bioinformaticians within the CALYM Institute's research network

### PERSPECTIVES FOR 2025

- Strong activity on the BIDIFLY project**
  - > **Forecast:** receipt of Whole Exome Sequencing data for the entire cohort; continuation of RNAseq analyses
- Participation in many other projects**
  - > **3 examples:** ALKOBS (ALK-positive anaplastic large cell lymphoma), DLBCL\_EBV+ (Epstein-Barr virus-positive diffuse large B-cell lymphoma), INTENSIFY (diffuse large B-cell lymphoma)
- Evolution of high-throughput sequencing data analysis tools**
  - > **Objective:** to develop tools that enable reproducible and scalable data analysis, providing greater flexibility and modularity





## 03 LYSA-P/LYSA-BIO platform activities



The activity of the LYSA-P/LYSA-BIO platform remained strong in 2024: management of a portfolio of 22 ongoing clinical studies, launch of 2 new trials, and participation in 25 data reuse studies (DRS). The new LYSA-P/LYSA-BIO organization continued to take shape, marked in particular by the relocation of the LYSA-P platform and the arrival of new team members. The year 2025 is already shaping up to be intense, with four study launches projected.

### 2024 HIGHLIGHTS

#### Sustained activity

- > 22 active clinical studies
- > 49 review sessions with expert pathologists
- > 5 data exports to the biostatistics teams
- > 4 clinical study launches, including 2 with nearly 200 patients recruited in 9 months
  - > 200 sampling kits prepared, shipped to sites, and resupplied
  - > 600 samples collected, frozen, or centralized
- > 25 data reuse studies (DRS)

#### Implementation of the new LYSA-P/LYSA-BIO structure

- > Relocation of the LYSA-P platform, now integrated within the pathology department at Henri Mondor Hospital in Créteil
- > Appointment of a Director for the new Biology and Pathology department
- > Team consolidation through the creation of several positions: project coordinator, biological collection coordinator, project manager

#### Inventory of LYSARC legacy collections

- > Objective: to update the biological collections and enable the conduct of new data reuse studies (DRS)

#### Evaluation of a new version of the LYSABANK® biobanking tool

- > Objective: to professionalize the management and monitoring of clinical trials and the valorization of LYSA/LYSARC biological and histopathological collections

### 2025 PERSPECTIVES

#### Positive activity momentum

- > Management of 10 long-term studies
- > Launch of 4 planned studies in the first half of 2025 with new sample handling techniques

#### Ongoing structuring of LYSA-P/LYSA-BIO

- > Inauguration of the new LYSA-P premises
- > Completion of the organizational transformation aimed at implementing new operational processes to improve efficiency and foster collaboration across all LYSARC departments and partner platforms

#### Deployment of the new sample and collection management software

- > Key challenge: migration of 15 years of historical data to enable reuse in ongoing and future projects (notably the BIDIFLY project)

## 04 LYSA-IM platform activities



In 2024, the LYSA-IM platform confirmed the momentum observed in 2023. Clinical activity remained steady, with around fifteen studies in the portfolio during the year (15 active studies and 3 in the startup phase). Research activity remained strong, with 38 data reuse studies (DRS). The outlook for 2025 continues along this trajectory, with the continuation of major projects and the launch of new initiatives.

### 2024 HIGHLIGHTS

#### Dynamic clinical activity

- > 15 active studies with centralization and rereading of medical imaging exams
- > Involvement in 3 new clinical studies launched in 2024
- > 4 clinical study analyses
- > 8 valorizations (4 publications + 4 congress valorizations) based on centralized rereading data
- > 5 studies closed and archived

#### Sustained scientific research activity

- > 38 data reuse study (DRS) projects
- > 7 congress valorizations (6 posters + 1 oral communication)

#### Completion of a new structuring project

- > Production deployment of the PACS (Picture Archiving Communication System) to store all imaging data in a secure environment (42,000 medical imaging exams)

### 2025 PERSPECTIVES

#### Confirmation of the positive dynamic for clinical activity

- > Expected clinical activity level equivalent to 2024
- > Launch of new studies, including a high-stakes project for the LYSA-IM platform: a study requiring rereading of brain MRIs, a modality that has been little explored until now

#### Promising momentum for scientific research activity

- > Continuation of DRS projects, including analysis of data collected through the TEP-CART and BIDIFLY projects
- > Expansion of the team with the recruitment of a Data Scientist
- > Launch of a new program in collaboration with FILO (French Innovative Leukemia Organization) on chronic lymphocytic leukemia (CLL) and Richter's syndrome
- > Launch of a research project based on data from an industrial partner (Bristol Myers Squibb)

### FOCUS ON 4 KEY PROJECTS



#### CLINICAL STUDIES

##### Launch of the CARMOD project

- > Inclusion criteria list includes an imaging criterion resulting from LYSA-IM research work

##### Launch of the MorningLyte protocol

- > Implementation of an independent response review solution

#### DATA REUSE STUDIES (DRS)

##### TEP-CART project

- > **Objective:** to better understand the role of positron emission tomography (PET) in the management of patients receiving CAR-T therapy
- > Creation by LYSA-IM of a PET exam database of about 800 patients included in the DESCAR-T registry (first cohort in 2023, three more in 2024)

##### BIDIFLY project

- > **Objective:** to leverage artificial intelligence to advance research on follicular lymphoma
- > Substantial work by LYSA-IM to structure all imaging data held by LYSARC for this lymphoma subtype



# Appendix

## PUBLICATIONS 2024 - 51 ARTICLES



**01** Alig SK, Shahrokh Esfahani M, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, Jin MC, Olsen M, Telenius A, Mutter JA, Schroers-Martin JG, Swarder BJ, Rai S, King DA, Schultz A, Bögeholz J, Su S, Kathuria KR, Liu CL, Kang X, Strohband MJ, Langfitt D, Pobre-Piza KF, Surman S, Tian F, Spina V, Tousseyn T, Buedts L, Hoppe R, Natkunam Y, Fornecker L-M, Castellino SM, Advani R, Rossi D, Lynch R, Ghesquières H, Casasnovas O, Kurtz DM, Marks LJ, Link MP, André M, Vandenbergh P, Steidl C, Diehn M, Alizadeh AA. **Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.** Nature 2024;625:778–87.



**02** Federico M, Fortpied C, Stepanishyna Y, Gotti M, van der Maazen R, Cristinelli C, Re A, Plattel W, Lazarovici J, Merli F, Specht L, Schiano de Colella J-M, Hutchings M, Versari A, Edeline V, Stamatoulas A, Girinsky T, Ricardi U, Aleman B, Meulemans B, Tonino S, Raemaekers J, André M. **Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.** JCO 2024;42:19–25.



**03** Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho J-M, Jimenez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Nunes A, Reitan J, Wade SW, Salles G. **Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.** Leuk Lymphoma 2024;65:14–25.



**04** Maerevoet M, Casasnovas O, Cartron G, Morschhauser F, Thieblemont C, Bouabdallah K, Feugier P, Szablewski V, Becker S, Tilly H. **Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma—Final Analysis.** Cancers 2024;16:2672.



**05** Messéant O, Drieux F, Sako N, Fataccioli V, Camus V, Robe C, Houot R, Tas P, Llamas-Gutierrez F, Lamaison C, Abraham J, Delage-Corre M, Benguerfi S, Bossard J-B, Gaulard P, Lemonnier F. **Clinical and histological study of follicular helper T-cell lymphomas with indolent evolution.** Eur J Cancer 2024;197:113479.



**06** Mouheb M, Pierre-Jean M, Devillers A, Fermé C, Benchalal M, Manson G, Le Jeune F, Houot R, Palard-Novello X. **Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18F-FDG PET/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma.** Clinical Nuclear Medicine 2024;49:e1.



**07** Carlier T, Frécon G, Mateus D, Rizkallah M, Kraeber-Bodéré F, Kanoun S, Blanc-Durand P, Itti E, Gouill SL, Casasnovas R-O, Bodet-Milin C, Bailly C. **Prognostic Value of 18F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.** Journal of Nuclear Medicine 2024;65:156–62.



**08** Cottreau AS, Rebaud L, Trotman J, Feugier P, Nastoupil LJ, Bachy E, Flinn IW, Haïoun C, Ysebaert L, Bartlett NL, Tilly H, Casasnovas O, Ricci R, Portugues C, Buvat I, Meignan M, Morschhauser F. **Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.** Annals of Oncology 2024;35:130–7.



**09** Ghesquières H, Cherblanc F, Belot A, Micon S, Bouabdallah KK, Esnault C, Fornecker L-M, Thokagevistik K, Bonjour M, Bijou F, Haïoun C, Morineau N, Ysebaert L, Damaj G, Tessoulin B, Guidez S, Morschhauser F, Thieblemont C, Chauchet A, Gressin R, Jardin F, Fruchart C, Labouré G, Fouillet L, Lionne-Huyghe P, Bonnet A, Lebras L, Amorim S, Leyronnas C, Olivier G, Guieze R, Houot R, Launay V, Drénou B, Fitoussi O, Detournignies L, Abraham J, Soussain C, Lachenal F, Pica GM, Fogarty P, Cony-Makhoul P, Bernier A, Le Guyader-Peyrou S, Monnerieu A, Boissard F, Rossi C, Camus V. **Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.** Blood Advances 2024;8:296–308.



**10** Wilson MR, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Lees C, Fox C, Preston G, Ahearne M, Strüßmann T, Clavert A, Rusconi C, Ku M, Khwaja J, Narkhede M, Lewis K, Durot E, Smith J, Renaud L, Ferreri AJM, El-Galaly T, Cwynarski K, McKay P, Eyre TA.

**Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.**

Am J Hematol 2024;99:E46–50.



**11** Bommier C, Zucca E, Chevret S, Conconi A, Nowakowski G, Maurer MJ, Cerhan JR, Thieblemont C, Lambert J.

**Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy.**

Blood 2024;143:422–8.



**12** Gium KB, Cottreau A-S, Vercellino L, Rebaud L, Clerc J, Casasnovas O, Morschhauser F, Thieblemont C, Buvat I.

**Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.**

Journal of Nuclear Medicine 2024;65:313–9.



**13** Krug A, Tosolini M, Madji Hounoum B, Fournié J-J, Geiger R, Pecoraro M, Emond P, Gaulard P, Lemonnier F, Ricci J-E, Verhoeyen E.

**Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment.**

J Exp Clin Cancer Res 2024;43:43.



**14** Hoster E, Delfau-Larue M-H, Macintyre E, Jiang L, Stilgenbauer S, Vehlting-Kaiser U, Salles G, Thieblemont C, Tilly H, Wirths S, Feugier P, Hübel K, Schmidt C, Ribrag V, Kluin-Nelemans JC, Dreyling M, Pott C, on behalf of the European MCL MRD Working Group and the European MCL Network. **Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.**

JCO 2024;42:538–49.



**15** Sarkozy C, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Damaj G, Gastinne T, Tessoulin B, Ribrag V, Casasnovas O, Haïoun C, Houot R, Jardin F, Van Den Neste E, Cheminant M, Morschhauser F, Callanan M, Safar V, Gressin R, Hermine O, Le Gouill S. **Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.**

J Clin Oncol 2024;42:769–73.



**16** Ghesquières H, Krzisch D, Nicolas-Virelizier E, Kanoun S, Gac AC, Guidez S, Touati M, Laribi K, Morschhauser F, Bonnet C, Wautier-Rascalou A, Orsini-Piocelle F, André M, Fournier M, Morand F, Berriolo-Riedinger A, Burroni B, Damotte D, Traverse-Glehen A, Quittet P, Casasnovas O.

**The Phase II LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.**

Blood 2024;143:983–95.



**17** Laurent C, Dietrich S, Tarte K. **Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm.**

Blood 2024;143:1080–90.



**18** Vic S, Thibert J-B, Bachy E, Cartron G, Gastinne T, Morschhauser F, Le Bras F, Bouabdallah K, Despas F, Bay J-O, Rubio M-T, Mohty M, Casasnovas O, Choquet S, Castilla-Llorente C, Guidez S, Loschi M, Guffroy B, Carras S, Drieu La Rochelle L, Guillet M, Houot R.

**Transfusion needs after CAR-T cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).**

Blood Adv 2024;8:1573–85.



**19** Muller M, Broséus J, Guilloteau A, Wasse S, Thieblemont C, Nancey S, Cadiot G, Amiot A, Laharie D, Vieujean S, Bouhnik Y, Martineau C, Michiels C, Hebuterne X, Savoye G, Franchimont D, Seksik P, Beaugier L, Maynadié M, Feugier P, Peyrin-Biroulet L. **Lymphoma in Patients with Inflammatory Bowel Disease: A Multicentre Collaborative Study Between GETAID and LYSA.**

J Crohns Colitis 2024;18:533–9.



**20** Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas R-O, Ysebaert L, Damaj GL, Guidez S, Pica GM, Kim WS, Lim ST, Andre M, Gutiérrez N, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Tucci A, Fogarty P, Farhat H, Abraham J, Abarah W, Belmecheri F, Ribrag V, Delfau-Larue M-H, Cottreau A-S, Itti E, Li J, Delarue R, de Leval L, Morschhauser F, Bachy E.

**Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.**

J Clin Oncol 2024;42:1612–8.





- 21 Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, Touzeau C, Leleu X, Moya N, Harel S, Perrot A, Bories P, Vincent L, Lamure S, Mohty M, Malard F, Manier S, Yakoub-Agha I, Schiano De Colella J-M, Brisou G, Talbot A, Decaux O, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Moreau P, Arnulf B, Intergroupe Francophone du Myélome. **French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.** Br J Haematol 2024.
- 22 Arcaini L, Bommier C, Alderuccio JP, Merli M, Fabbri N, Nizzoli ME, Maurer MJ, Tarantino V, Ferrero S, Rattotti S, Talami A, Murru R, Khurana A, Mwangi R, Deodato M, Cencini E, Re F, Visco C, Feldman AL, Link BK, Delamain MT, Spina M, Annibali O, Pulsoni A, Ferreri AJM, Stelitano CC, Pennese E, Habermann TM, Marcheselli L, Han S, Reis IM, Paulli M, Lossos IS, Cerhan JR, Luminari S. **Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.** EClinicalMedicine 2024;72:102592.
- 23 Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas R-O, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker L-M, Delfau-Larue M-H, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F. **Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, Phase III study.** Lancet Haematol 2024;11:e406-14.
- 24 Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, André M, Le Bras F, Plattel WJ, Henry-Amar M, Hutchings M, Maraldo MV. **Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials.** J Cancer Surviv 2024;18:727-38.
- 25 Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, Moreau A, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Barbieux S, Corm S, Banos A, Fouillet L, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouabdallah K, Amorim S, Garidi R, Voillat L, Joly B, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Burrioni B, Callanan M, Le Gouill S, Gressin R. **Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.** Haematologica 2024;109:1857-65.
- 26 Veleanu L, Lamant L, Sibon D, Therapeutic Strategy Project for Adult ALK+ ALCL. **Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin.** N Engl J Med 2024;390:2129-30.
- 27 Krug A, Mhaidly R, Tosolini M, Mondragon L, Tari G, Turtos AM, Paul-Bellon R, Asnafi V, Marchetti S, Di Mascio L, Travert M, Bost F, Bachy E, Argüello RJ, Fournié J-J, Gaulard P, Lemonnier F, Ricci J-E, Verhoeyen E. **Dependence on mitochondrial respiration of malignant T cells reveals a new therapeutic target for angioimmunoblastic T-cell lymphoma.** Cell Death Discov 2024;10:292.
- 28 Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A, Gastinne T, Lamy T, Roussel M, Bouabdallah K, Beauvais D, Cartron G, Bay J-O, Blaise D, Rubio M-T, Mohty M, Le Bras F, Casasnovas O, Guy J, Guidez S, Llorente CC, Hermine O, La Rochelle LD, Carras S, Guffroy B, Caillat-Zucman S, Houot R, Le Gouill S. **Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.** Haematologica 2024.
- 29 Durot E, Roos-Weil D, Chauchet A, Decroocq J, Di Blasi R, Gastinne T, Bensaber H, Cheminant M, Jacquet C, Guidez S, Gros F-X, Bachy E, Coste A, Cony-Makhoul P, Treon SP, Delmer A, Reshef R, Le Gouill S, Castillo JJ, Houot R. **High efficacy of CD19 CAR-T cells in patients with transformed Waldenström macroglobulinemia.** Blood 2024;143:2804-7.
- 30 Lan CL, Belot A, Golfier C, Audin B, Sesques P, Bernier A, Safar V, Ferrant E, Lazareth A, Lequeu H, Karlin L, Ghergus D, Maarek A, Aussedat G, Idlhaj M, Salles G, Cherblanc F, Bachy E, Ghesquieres H. **Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.** Hematol Oncol 2024;42:e3297.
- 31 Yuta Ito, Amira Marouf, Yasunori Kogure, Junji Koya, Raphaël Liévin, Bruneau J, Tabata M, Saito Y, Shingaki S, Yuasa M, Yamaguchi K, Murakami K, Weil R, Vavasseur M, Andrieu GP, Latiri M, Veleanu L, Dussiot M, André I, Joshi A, Lagresle-Peyrou C, Magerus A, Chaubard S, Lavergne D, Bachy E, Brunet E, Fataccioli V, Brouzes C, Laurent C, de Leval L, Traverse-Glehen A, Bossard C, Parrens M, Meignin V, Philippe L, Rossignol J, Suarez F, Michot J-M, Tournilhac O, Damaj G, Lemonnier F, Bôle-Feysot C, Nitschké P, Tesson B, Laurent C, Molina T, Asnafi V, Watatani Y, Chiba K, Okada A, Shiraishi Y, Tsukita S, Izutsu K, Miyoshi H, Ohshima K, Sakata S, Dobashi A, Takeuchi K, Sanada M, Gaulard P, Jaccard A, Ogawa S, Hermine O, Kataoka K, Couronné L. **Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma.** Cancer Res 2024;84:2181-201.
- 32 Crochet G, Iacoboni G, Couturier A, Bachy E, Iraola-Truchuelo J, Gastinne T, Cartron G, Fradon T, Lesne B, Kwon M, Gounot R, Martínez-Cibrian N, Castilla-Llorente C, Abrisqueta P, Guerreiro M, Sarkozy C, Aspa-Cilleruelo JM, Camus V, Guidez S, Chauchet A, Deconinck E, Bouabdallah K, Bosch F, Barba P, Morschhauser F, Houot R. **Efficacy of CAR-T cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma.** Blood 2024;144:334-8.
- 33 Sarkozy C, Callanan M, Thieblemont C, Obéric L, Burrioni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griotlet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue M-H, Hermine O, Macintyre E, Le Gouill S. **Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.** Blood 2024;144:262-71.
- 34 Stathis A, Piroso MC, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FG, Merli F, Guièze R, Gyan E, Gini G, Marino D, Gressin R, Morschhauser F, Cavallo F, Palombi F, Conconi A, Tessoulin B, Tilly H, Zanni M, Cabras MG, Capochiani E, Califano C, Celli M, Pulsoni A, Angrilli F, Occhini U, Casasnovas R-O, Cartron G, Devizzi L, Haïoun C, Liberati AM, Houot R, Merli M, Pietrantonio G, Re F, Spina M, Landi F, Cavalli F, Bertoni F, Rossi D, Ielmini N, Borgo E, Luminari S, Zucca E, Thieblemont C. **IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.** Haematologica 2024;109:2564-73.
- 35 Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros F-X, le Bras F, Bories P, Choquet S, Rubio M-T, Iacoboni G, O'Reilly M, Casasnovas R-O, Bay J-O, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E. **Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR-T cells in large B-cell lymphoma.** J Hematol Oncol 2024;17:61.
- 36 Menez S, Bourbon E, Gounot R, Tudesq J-J, Moya N, Houot R, Bachy E. **CAR-T cells in very elderly (≥80 years) lymphoma patients: a DESCAR-T analysis.** Leuk Lymphoma 2024:1-4.
- 37 Frontzek F, Renaud L, Dührsen U, Poeschel V, Bernard S, Chartier L, Ketterer N, Récher C, Fitoussi O, Held G, Casasnovas O, Haïoun C, Mounier N, Tilly H, Morschhauser F, Le Gouill S, Karsten IE, Duns G, Steidl C, Scott DW, Klapper W, Rosenwald A, Ott G, Molina T, Lenz G, Ziepert M, Altmann B, Thieblemont C, Schmitz N. **Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective Phase II and III trials-a LYSA and GLA/DSHNHL collaboration.** Leukemia 2024.
- 38 Camus V, Houot R, Brisou G, Tessoulin B, Bailly S, Sesques P, Decroocq J, Krzisch D, Obéric L, Lemonnier F, Bouabdallah K, Campidelli A, Tounes L, Abraham J, Herbaux C, Morschhauser F, Damaj G, Guidez S, Carras S, Fornecker L-M, Choquet S, Hermine O, Paillasa J, Chauchet A, Casasnovas O, Drieu La Rochelle L, Castilla-Llorente C, Joris M, Dupont V, Marquet A, Le Gouill S, Jardin F. **Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.** Blood Adv 2024:bloodadvances.2024013726.



- 39 Rabian F, Beauvais D, Marchand T, Furst S, Huynh A, Brissot E, Maury S, Gabellier L, Chevallier P, Loschi M, Nguyen Quoc S, Balsat M, Lafon I, Fayard A, Camus V, Simand C, Moya N, Castilla-Llorente C, Joris M, Berceanu A, Thiebaut-Bertrand A, Lheritier V, Gehlkopf E, Roth Guepin G, Leguay TT, Boissel N. **Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with R/R B-ALL : A GRAALL study from the DESCAR-T registry.** Blood Advances 2024;bloodadvances.2024013962. 
- 40 Anota A, Basset M, Charton E, Bommier C, Efficace F, Dupuis J, Cottone F, Bouabdallah KK, Mollevi C, Ysebaert L, Winter A, Bijou F, Préau M, Chauchet A, Bernier A, Fornecker L-M, Hafirassou H, Carras S, Lachenal F, Lionne-Huyghe P, Detournignies L, Leyronnas C, Drénou B, Peyrou SLG, Abraham J, Monnereau A, Fouillet L, Morschhauser F, Rossi C, Belot A, Ghesquières H. **Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.** Eur J Cancer 2024;208:114210. 
- 41 Boellaard R, Buvat I, Nioche C, Ceriani L, Cottereau A-S, Guerra L, Hicks RJ, Kanoun S, Kobe C, Loft A, Schöder H, Versari A, Voltin C-A, Zwezerijnen GJC, Zijlstra JM, Mikhaeel NG, Gallamini A, El-Galaly TC, Hanoun C, Chauvie S, Ricci R, Zucca E, Meignan M, Barrington SF. **International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation.** J Nucl Med 2024;65:1343–8. 
- 42 Syrykh C, DI Proietto V, Brion E, Copie-Bergman C, Jardin F, Dartigues P, Gaulard P, Jo Molina T, Briere J, Oberic L, Haioun C, Tilly H, Maussion C, Morel M, Schiratti J-B, Laurent C. **MYC Rearrangement Prediction from LYSA Whole Slide Images in Large B-cell Lymphoma: A Multi-centric Validation of Self-supervised Deep Learning Models.** Mod Pathol 2024;100610. 
- 43 Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, Turlure P, Reimer P, Wagner-Drouet E, Sanhes L, Houot R, Roussel M, Kroschinsky F, Dreger P, Viardot A, de Leval L, Rosenwald A, Gaulard P, Wulf G, Villate A, Latiere C, Elmaagacli A, Glass B, Poeschel V, Damaj G, Sibon D, Durot E, Bilger K, Banos A, Haenel M, Dreyling M, Keller U, Tiab M, Drenou B, Cornillon J, Nguyen S, Robin M, Nickelsen M, Trümper L, Lenz G, Ziepert M, Schmitz N, French Lymphoma Study Association (LYSA), Société Francophone de greffe de moelle et Thérapie Cellulaire (SFGM-TC), German Lymphoma Alliance (GLA), French Lymphoma Study Association (LYSA), Société Francophone de greffe de moelle et Thérapie Cellulaire (SFGM-TC), German Lymphoma Alliance (GLA). **Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).** J Clin Oncol 2024;JCO2400554. 
- 44 Camus V, Viennot M, Viailly P-J, Drieux F, Veresezan E-L, Bobée V, Rainville V, Bohers E, Sesques P, Haioun C, Durot E, Bayaram M, Rossi C, Martin L, Penther D, Kaltenbach S, Bruneau J, Paillassa J, Tournilhac O, Gower N, Willaume A, Antier C, Renaud L, Leveque E, Decazes P, Becker S, Tonnelet D, Gaulard P, Tilly H, Molina T, Traverse-Glehen A, Donzel M, Ruminy P, Jardin F. **Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5' RACE.** Blood Adv 2024;bloodadvances.2024013723. 
- 45 Ray M, Castaigne J-G, Zang A, Patel A, Hancock E, Brighton N, Bachy E. **A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry.** Adv Ther 2024. 
- 46 Juul SJ, Rossetti S, Aleman BMP, van Leeuwen FE, van der Kaaij MAE, Giusti F, Meijnders P, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Krzisch D, Bigenwald C, Stamatoullas A, André M, Plattel WJ, Hutchings M, Maraldo MV. **Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials.** J Cancer Surviv 2024. 
- 47 Bommier C, Donzel M, Rossi C, Fornecker LM, Bijou F, Chauchet A, Lebras L, Ysabaert L, Haioun C, Bouabdallah K, Gastinne T, Morineau N, Amorim S, Jardin F, Abraham J, Lamy de la Chapelle T, Gressin R, Fouillet L, Fruchart C, Olivier G, Morschhauser F, Cherblanc F, Belot A, Le Guyader S, Monnereau A, Ghesquieres H, Thieblemont C. **Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.** Hematol Oncol 2024;42:e3314. 
- 48 Chartier L, Belot A, Chaillol I, Elsensohn M-H, Portugues C, Fournier M, Joubert C, Gat E, Pizot C, Fogarty P, Murairi T, Ammar RO, Paget J, Cherblanc F, Ricci R, Vercellino L, Kanoun S, Cottereau A-S, Thieblemont C, Casasnovas O. **Precautions to Consider in the Analysis of Prognostic and Predictive Indices.** Journal of Nuclear Medicine 2024;65:1672–8. 
- 49 Di Staso R, Casadei B, Locke FL, Jain M, Voorhees TJ, Kittai AS, Bastos-Oreiro M, Gutiérrez A, Martin Garcia-Sancho A, Terol MJ, Mead M, Maranzano MJ, Iacoboni G, Barba P, Kwon M, Bailen R, Reguera-Ortega JL, Mian A, Hill B, Bachy E, Morschhauser F, Houot R, Thieblemont C, Le Gouill S, Masetti R, Gori D, Broccoli A, Zinzani PL, Argnani L. **Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.** Blood Cancer J 2024;14:197. 
- 50 Rossi C, Manson G, Marouf A, Cabannes-Hamy A, Nicolas-Virelizier E, Maerevoet M, Alcantara M, Molina L, Ceraulo A, Poirée M, Galtier J, Diop N, Delette C, Segot A, Dubois S, Waultier A, Bernard S, Noël R, Guidez S, Kohn M, Bailly S, Moatti H, Touati M, Renaud L, Kanoun S, Cottereau A-S, Kirova Y, Peignaux K, Dourthe M-E, Simonin M, Leblanc T, Quéro L, Krzisch D, Duléry R, Grenier A, Gastinne T, Casasnovas O, Gallamini A, André M, Morschhauser F, Deau B, Fornecker L-M, Ghesquières H. **Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.** European Journal of Cancer 2024;213:115073. 
- 51 Laurent C, Trisal P, Tesson B, Seth S, Beyou A, Roulland S, Lesne B, Van Acker N, Cerapio J-P, Chartier L, Guille A, Stokes ME, Huang CC, Huet S, Gandhi AK, Morschhauser F, Xerri L. **Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance.** Blood 2024;144:2503–16. 





## CONGRESS ORALS AND POSTER PRESENTATIONS - 2024



**42**  
oral  
presentations

**30**  
posters

### JOURNÉE DE LA RECHERCHE CLINIQUE DE L'ASSOCIATION FRANÇAISE DES CROS (AFCROS) | PARIS - FRANCE | 14 MARCH 2024

#### 2 oral presentations

- Belot, A|Comparaisons indirectes : pourquoi, quand et comment ? Expérience du LYSARC dans la recherche sur les lymphomes
- Cartron, G|Construction d'un algorithme de ciblage des patients atteints d'un lymphome diffus à grandes cellules B (LDGCB) dans le Système National de Données de Santé (SNDS)

### CONGRÈS DE LA SOCIÉTÉ FRANÇAISE D'HÉMATOLOGIE (SFH) | PARIS - FRANCE | 27 TO 29 MARCH

#### 12 oral presentations

- Ysebart, L|Expérience française de l'efficacité et de la tolérance des CAR-T cells chez les patients avec un lymphome folliculaire en rechute/réfractaire: Une analyse du registre DESCAR-T du LYSA
- Crochet, G|Les cellules CAR-T conservent leur efficacité chez les patients atteints d'un lymphome B à grandes cellules en rechute ou réfractaire préalablement traités par des anticorps bispécifiques
- Renaud, L|Identification et caractérisation Clinique des rechutes SNC de lymphome B diffus à grandes cellules parmi 19 essais thérapeutiques Prospectifs de Phase II et III-une analyse conjointe LYSA et GLA/DSHNHL
- Manson, G|Cinétique de réponse après CAR-T cells pour les lymphomes diffus à grandes cellules B en 3e ligne de traitement ou plus : une analyse du registre français DESCAR-T
- Durot, E|CAR T-cells anti-CD19 dans les transformations histologiques de macroglobulinémie de Waldenström : une étude collaborative du registre DESCAR-T et de 2 centres US
- Brisou, G|Axicabtagene Ciloleucel dans la vraie vie pour les patients atteints de lymphome B à grandes cellules en deuxième ligne : Premiers résultats du registre LYSA/DESCAR-T
- Ferment, B|Idecabtagene vicleucel dans le traitement du myélome multiple : actualisation de l'expérience nationale en vie réelle (étude FENIX)
- Al Tabaa, Y|Influence du volume métabolique sur la réponse précoce dans le traitement par axicabtagene ciloleucel en 2<sup>ème</sup> ligne dans les lymphomes B diffus à grandes cellules : étude ancillaire Phase II ALYCANTE
- Cartron, G|Glofitamab (anti-CD3xCD20) chez les patients atteints d'un lymphome en rechute ou réfractaire après un CAR-T cells anti-CD19 : Résultats de l'étude de phase II BiCAR conduite par le LYSA

- Bommier, C|Nouveaux marqueurs et qualité de vie dans le LZM
- Bourbon, e|CAR-T cells et lymphomes T
- Tessoulin, B|Echantillons ctDNA du protocole LyMA à Stanford, une coopération LYSA/LYSARC/GOELAMS

#### 10 posters

- Guidez, S|Caractéristiques et évolution des patients présentant un lymphome diffus à grandes cellules B en 1<sup>ère</sup> rechute précoce : étude multicentrique basée sur la cohorte prospective française REALYSA
- Camus, Vincent|Romidepsine-CHOP versus CHOP en traitement de 1<sup>ère</sup> ligne des lymphomes T périphériques : résultats de l'analyse finale de l'essai de phase III randomisée Ro-CHOP
- Nsiala, L|REAGIP « Intérêt d'une cohorte populationnelle haute-résolution pour évaluer la représentativité d'une étude en vie-réelle : premiers résultats d'un travail collaboratif entre REALYSA et le Registre Général des Cancers du Poitou-Charentes »
- Cantrelle, C|Impact des facteurs socio-économiques individuels et contextuels sur les délais extrêmes entre le diagnostic et le traitement des patients atteints de lymphomes diffus à grandes cellules issus de la cohorte REALYSA
- Al Tabaa, Y|Le volume métabolique total influence la réponse chez les patients LBDGC 3L+ traités par CAR-T cells : Résultats préliminaires de l'analyse TEP-FDG du registre national DESCAR-T
- Charton, E|Qualité de vie après Axi-cel en 2<sup>ème</sup> ligne de lymphome à grandes cellules B chez des patients inéligibles à une autogreffe : résultats de l'essai ALYCANTE
- Sarkozy, C|Résultat de l'étude de phase II Epi-RCHOP évaluant l'efficacité du Tazemetostat en combinaison avec le RCHOP chez les sujets âgés atteints d'un LBDGC au diagnostic
- Ghesquieres, H|Evaluation du Tislélizumab, anticorps anti-PD-1, chez des patients atteints d'un lymphome de Hodgkin classique en rechute/réfractaire : étude prospective multicentrique de Phase II TIRHOL BGB-A317-210 du LYSA
- Jardin, F|L'ADN tumoral circulant (ADNtc) plasmatique comme alternative à l'ADN tissulaire pour le génotypage du lymphome diffus à grandes cellules B (LDGCB) : résultats de l'étude POLARIX
- Ysebaert, L|Tazemetostat en combinaison avec R-CHOP dans le traitement de 1<sup>ère</sup> ligne des lymphomes folliculaires à haut risque et forte masse tumorale (Epi-RCHOP) : une étude de phase II du LYSA

### EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES (ESCMID) | BARCELONA - SPAIN | 27 TO 30 APRIL 2024

#### 1 poster

- Bouvier, A; Melica, G|Invasive Fungal Infections after CAR-T cell Therapy for B-Cell Lymphoma in a nationwide retrospective cohort - Where, when and why ?

### MCL NETWORK | MUNICH - GERMANY | 13-14 MAY 2024

#### 1 oral presentation

- Le Bris, Yannick|ABERRANT CYTOPLASMIC EXPRESSION OF P16 IS A NEW STRONG PROGNOSTIC MARKER IN YOUNG MCL PATIENTS TREATED BY FRONTLINE CYTARABINE-BASED IMMUNOCHEMOTHERAPY, A STUDY FROM THE LYSA GROUP, NORDIC LYMPHOMA GROUP AND THE EUROPEAN MCL NETWORK

### CONFÉRENCE D'ÉPIDÉMIOLOGIE CLINIQUE (EPICLIN) | DIJON - FRANCE | 15 TO 17 MAY 2024

#### 1 oral presentation

- Anota, A|REALYQOL « Evolution de la qualité de vie des patients atteints d'un lymphome diffus à grandes cellules B après la première ligne de traitement participant à la cohorte prospective REALYSA »

### EUROPEAN HEMATOLOGY ASSOCIATION (EHA) | MADRID - SPAIN | 13 TO 16 JUNE 2024

#### 4 oral presentations

- Galtier, J; Bouabdallah, K|EXCELLENT OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL B CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL : A STUDY FROM THE FRENCH DESCAR-T NATIONAL REGISTRY
- Stephan, P|TRANSCAR: A Real-life outcome study of relapsed/refractory transformed indolent non-Hodgkin lymphoma in the context of CAR-T cells : A DESCART analysis
- Guffroy, B; Bories, P|Real-world assessment of anti-CD19 CAR-T cells in patients aged 75 years and older with Relapsed or Refractory Diffuse Large B Cell Lymphoma: a LYSA study from the DESCAR-T registry
- Cayla, S|Outcomes of Patients with Relapsed/Refractory Multiple Myeloma following early Progression after Ide-Cel Therapy : an IFM Study from the DESCAR-T Registry

#### 8 posters

- Camus, Vincent|Outcomes in patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide post-CD19-targeting CAR-T therapy: a LYSA study from the DESCAR-T registry
- Al Tabaa, Y|Early PET evaluation at Day 14 post axicabtagene ciloleucel infusion predicts outcome in large B-cell lymphoma: results from the ALYCANTE phase II study
- Cristinelli, C|Clinical characteristics, treatments, and outcomes of Large B-cell Lymphoma patients in third-line therapy included between 2018 and 2023 in the French prospective multicentric REALYSA cohort

- Guidez, S|Clinical characteristics, treatment options and outcome of refractory and early relapse Large B Cell Lymphoma (LBCL) patients included in the REALYSA cohort before CAR-T cells era
- Camus, Vincent|Deciphering the BCR repertoire via 5' Rapid Amplification of cDNA Ends (5'RACE) identifies Primary Mediastinal B-Cell Lymphoma cases with High Tumor Density and Poorer Outcomes
- Herbaux, C|EARLYMIND, A RETROSPECTIVE MULTICENTER STUDY IN REAL-WORLD SETTINGS TO CHARACTERIZE TAFASITAMAB-LENALIDOMIDE EFFICACY IN TRANSPLANT-INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
- Lue, J|GENOMIC PROFILING IN A SUBGROUP ANALYSIS OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND EXTRANODAL (EN) SITES OF INVOLVEMENT IN THE PHASE III POLA-R-CHP VERSUS R-CHOP (POLARIX) STUDY
- Soussain, C|COLLABORATIVE ADVANCEMENTS IN DRUG DEVELOPMENT: LEVERAGING CEVI-PDX, THE ANNOTATED LYMPHOMA PDX COLLECTION FROM France

### COLLOQUE INTERNATIONAL SUR LE PARTENARIAT DE SOIN AVEC LES PATIENTS | LYON, CLERMONT-FERRAND, VIENNE, GRENOBLE - FRANCE | 25 TO 27 SEPTEMBER 2024

#### 2 oral presentations

- Le Guyader-Peyrou, S|Une VIDÉO élaborée POUR et AVEC les patients pour améliorer l'adhésion dans les études épidémiologiques : l'exemple de REALYSA
- Le Guyader-Peyrou, S|Constitution et animation d'un groupe de patients partenaires d'une étude épidémiologique de suivi en vie réelle de patients atteints de lymphomes (REALYSA)

### SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO) | PARIS - FRANCE | 9 TO 11 OCTOBER 2024

#### 3 oral presentations

- Sibon, David|Hepato-splenic T cell lymphoma
- Sarkozy, Clémentine|Grey Zone type NHL
- Manson, Guillaume|Classical Hodgkin lymphoma: National recommendations

### INTERNATIONAL SOCIETY FOR QUALITY OF LIFE RESEARCH (ISOQOL) | COLOGNE - GERMANY | 13 TO 16 OCTOBER 2024

#### 1 oral presentation

- Anota, A|Health-related quality of life and response shift effect of diffuse large B-cell lymphoma French relapse-free patients one year after diagnosis included in prospective real-life REALYSA cohort



**EUROPEAN SCHOOL OF HEMATOLOGY (ESH) |  
STOCKHOLM SWEDEN | 1 TO 3 NOVEMBER 2024**

**6 oral presentations**

- Bachy, Emmanuel|Follicular Lymphoma: Bispecific VS CAR-T
- Thieblemont, Catherine|Managing patients with diffuse large B cell lymphoma relapsing after CAR-T cell therapy
- Thieblemont, Catherine|New era in marginal zone lymphomas: IBTK new generation, bispecifics, CAR-T
- Lemonnier, François|Interactive case: Follicular T helper cell lymphomas: Biology and therapy
- Cheminant, Morgane|Case-based lecture: Relapsed and refractory: Novel agents including bispecifics, BTKIs and other agents
- Carras, Sylvain|Interactive case: Should all patients initiate treatment after diagnosis?

**EUROPEAN SCIENTIFIC FOUNDATION FOR  
LABORATORY HEMATO ONCOLOGY (ESLHO)  
SYMPOSIUM | LISBON PORTUGAL |  
7 NOVEMBER 2024**

**1 oral presentation**

- Milpied, Pierre|Spatial transcriptomics analyses of germinal center-derived B cell lymphomas

**AMERICAN SOCIETY OF HEMATOLOGY (ASH) |  
SAN DIEGO – UNITED STATES | 07 TO 10 DECEMBER  
2024**

**9 oral presentations**

- Le Gouill, Steven|Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase II Trial
- Gower, Nicolas|Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR-T cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A LYSA, Sfce and Graall Study from the Descar-T Registry
- Camus, Vincent|Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase III Gained Study Conducted By LYSA
- Aymard, M; Sarkozy, Clementine|Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T cell Therapy: A Descar-T Study By LYSA Group
- Boegeholz, Jan; Rossi, C|Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
- Munoz, Martinez; Carmen, Maria|Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, LYSARC, and Turkish Lymphoma Group
- Dubois, Sydney|Senior-IPI: An Easily Applicable and Meaningful Prognostic Index for First-Line LBCL Patients Older Than 80 Years Treated with Age-Adapted Immunochemotherapy

- Rossi, Cedric|Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
- Roulland, Sandrine|A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL

**11 posters**

- Mondello, Patrizia|Frontline R-CHOP and BR Have Similar Outcomes By SUV<sub>max</sub> in Follicular Lymphoma
- Callanan, Mary B.|Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A LYSA Study
- Bachy, Emmanuel|Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase II Valym Study from the LYSA
- Le Bris, Yannick|Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the LYSA Group, Nordic Lymphoma Group and the European MCL Network
- Guffroy, B; Bories, P|A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR-T cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A LYSA Study from the Descar-T Registry
- Clerico, Michele|CAR-T cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A LYSA Study from the Descar-T Registry
- Houot, Roch|Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial
- Camus, Vincent|Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
- Marouf, Amira|Outcomes of Patients Treated with Consolidative Brentuximab Vedotin after Transplant for Hodgkin Lymphoma at High Risk of Progression or Relapse: An Innovative Comparative Analysis Based on Propensity Score Weighting from Patients Included in 4 LYSA-Cohorts
- Michot, Jean-Marie|Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B LYSA Trials
- Arnulf, Bertrand|Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)







experts-recherche-lymphome.org



**> LinkedIn LYSA :**  
<https://www.linkedin.com/company/lysa-the-lymphoma-study-association/>



**> Twitter LYSA :**  
<https://twitter.com/LysaLymphoma>



**> LinkedIn CALYM :**  
<https://www.linkedin.com/company/institut-carnot-caly/>

**> LinkedIn LYSARC :**  
<https://www.linkedin.com/company/lysarc/>

